trial_id catype_expanded drug_list_expanded phase_expanded recruitmentstatus_expanded sensitivity_expanded eligibility_expanded states_expanded locations_expanded ACTRN12613000264785 catype:Cancer; catype:Solid tumour; catype_specific:Solid tumour phase:Phase 2; phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true preferential_trial_id:ACTRN12613000264785 recruitmentstates: ACTRN12614000552684 catype:Cancer; catype:Neuroblastic tumour; catype:Neuroblastoma; catype:Neurological cancer; catype:Peripheral nervous system tumour; catype:Solid tumour; catype_specific:Neuroblastoma therapy:Irinotecan; therapy:Temozolomide; therapy:alkylating_agent; therapy:cancer_therapy; therapy:cytotoxic_chemotherapy; therapy:topoisomerase_inhibitor; focused_drug:Irinotecan; focused_drug:Temozolomide; focused_therapy:Irinotecan; focused_therapy:Temozolomide; focused_therapy:alkylating_agent; focused_therapy:cancer_therapy; focused_therapy:cytotoxic_chemotherapy; focused_therapy:topoisomerase_inhibitor; focused_therapy_class:alkylating_agent; focused_therapy_class:topoisomerase_inhibitor phase:Phase 1 recruitmentstatus:NOT_YET_RECRUITING; recruitmentstatus_active:true sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dianhydrogalactitol; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10850; sensitive_to:Fotemustine; sensitive_to:Ifosfamide; sensitive_to:Irinotecan; sensitive_to:Irinotecan + Temozolomide; sensitive_to:Liposomal Irinotecan; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Procarbazine; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Topotecan; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + topoisomerase_inhibitor; sensitive_to:topoisomerase_inhibitor NOT therapy_recommendation:Irinotecan + Temozolomide:U; NOT therapy_recommendation:Irinotecan:U; NOT therapy_recommendation:Temozolomide:U; preferential_trial_id:ACTRN12614000552684; recruitment_status:NOT_YET_RECRUITING recruitmentstates: ACTRN12621000246886 catype:Acute myeloid leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Myeloid leukaemia; catype_specific:Acute myeloid leukaemia therapy:BRD4_inhibitor; therapy:SRA515; therapy:cancer_therapy; therapy:cancer_therapy,BRD4-targeting; focused_drug:SRA515; focused_therapy:BRD4_inhibitor; focused_therapy:SRA515; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,BRD4-targeting; focused_therapy_class:BRD4_inhibitor phase:Phase 2 recruitmentstatus:NOT_YET_RECRUITING; recruitmentstatus_active:true sensitive_to:BRD4_inhibitor; sensitive_to:SRA515 NOT therapy_recommendation:SRA515:U; preferential_trial_id:ACTRN12621000246886; recruitment_status:NOT_YET_RECRUITING recruitmentstates: ACTRN12622000037707 catype:Cancer; catype:Solid tumour; catype_specific:Solid tumour phase:Phase 2; phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true preferential_trial_id:ACTRN12622000037707 recruitmentstates:NSW,QLD,VIC; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:VIC facility:2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital; facility:3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; facility:3168 - Clayton - Monash Medical Centre; facility:4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre ACTRN12622000675729 catype:Cancer; catype:Central nervous system cancer; catype:Diffuse intrinsic pontine glioma; catype:Diffuse midline glioma; catype:Glioma; catype:H3K27M-mutant glioma; catype:High-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Central nervous system cancer; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:Diffuse midline glioma; catype_specific:High-grade glioma therapy:Bevacizumab; therapy:CAR-T-cell_therapy; therapy:CAR-T-cell_therapy,GD2-targeting; therapy:Cyclophosphamide; therapy:Fludarabine; therapy:GD2-iCAR-PBT; therapy:Radiotherapy; therapy:alkylating_agent; therapy:anti-VEGF_monoclonal_antibody; therapy:antimetabolite; therapy:autologous_CAR-T-cell_therapy; therapy:autologous_CAR-T-cell_therapy,GD2-targeting; therapy:cancer_therapy; therapy:cancer_therapy,GD2-targeting; therapy:cancer_therapy,VEGF-targeting; therapy:cell_therapy; therapy:cytotoxic_chemotherapy; therapy:immuno-oncology_therapy,VEGF-targeting; ; ; phase:Not Applicable recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Amsacrine; sensitive_to:Autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells; sensitive_to:Azacitidine; sensitive_to:Bendamustine; sensitive_to:Bevacizumab; sensitive_to:Bevacizumab + Cyclophosphamide + Fludarabine + GD2-iCAR-PBT; sensitive_to:Bisantrene; sensitive_to:Busulfan; sensitive_to:Bzacitidine; sensitive_to:Capecitabine; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cladribine; sensitive_to:Cyclophosphamide; sensitive_to:Cytarabine; sensitive_to:Dacarbazine; sensitive_to:Deflexifol; sensitive_to:Dianhydrogalactitol; sensitive_to:Fludarabine; sensitive_to:Fluorouracil; sensitive_to:Fotemustine; sensitive_to:GD2-iCAR-PBT; sensitive_to:GD2-iCAR-PBT + Radiotherapy; sensitive_to:Gemcitabine; sensitive_to:Hydroxyurea; sensitive_to:Ifosfamide; sensitive_to:Intensity Modulated Radiotherapy; sensitive_to:Lometrexol; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Methotrexate; sensitive_to:OncoSil; sensitive_to:Pemetrexed; sensitive_to:Procarbazine; sensitive_to:Radiotherapy; sensitive_to:Raltitrexed; sensitive_to:Streptozotocin; sensitive_to:Tegafur; sensitive_to:Tegafur-gimeracil-oteracil potassium; sensitive_to:Temozolomide; sensitive_to:Thioguanine; sensitive_to:Thiotepa; sensitive_to:Thoracic Radiation Therapy; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Trifluridine/Tipiracil; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + anti-VEGF_monoclonal_antibody + antimetabolite + autologous_CAR-T-cell_therapy,GD2-targeting; sensitive_to:anti-VEGF_monoclonal_antibody; sensitive_to:antimetabolite; sensitive_to:autologous_CAR-T-cell_therapy,GD2-targeting; sensitive_to:autologous_CAR-T-cell_therapy,GD2-targeting + radiotherapy; sensitive_to:radiotherapy (catype:Central nervous system cancer OR catype:High-grade glioma OR catype:Diffuse intrinsic pontine glioma OR catype:Diffuse midline glioma); NOT therapy_recommendation:Bevacizumab + Cyclophosphamide + Fludarabine + GD2-iCAR-PBT:U; NOT therapy_recommendation:Bevacizumab:U; NOT therapy_recommendation:Cyclophosphamide:U; NOT therapy_recommendation:Fludarabine:U; NOT therapy_recommendation:GD2-iCAR-PBT + Radiotherapy:U; NOT therapy_recommendation:GD2-iCAR-PBT:U; NOT therapy_recommendation:Radiotherapy:U; preferential_trial_id:ACTRN12622000675729 recruitmentstates:NSW; recruitmentstate:NSW facility:2031 - Randwick - Prince of Wales Hospital ACTRN12623000104651 catype:Cancer; catype:Central nervous system cancer; catype:Diffuse intrinsic pontine glioma; catype:Diffuse midline glioma; catype:Ependymoma; catype:Glioma; catype:H3K27M-mutant glioma; catype:High-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Central nervous system cancer; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:Diffuse midline glioma; catype_specific:Ependymoma therapy:Deflexifol; therapy:Fluorouracil; therapy:Leucovorin; therapy:Radiotherapy; therapy:antimetabolite; therapy:cancer_therapy; therapy:cytotoxic_chemotherapy; therapy:fluoropyrimidine; focused_drug:Deflexifol; focused_therapy:Deflexifol; focused_therapy:Fluorouracil; focused_therapy:antimetabolite; focused_therapy:cancer_therapy; focused_therapy:cytotoxic_chemotherapy; focused_therapy:fluoropyrimidine; focused_therapy_class:Fluorouracil phase:Phase 1 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Arfolitixorin; sensitive_to:Deflexifol; sensitive_to:Deflexifol + Fluorouracil + Leucovorin; sensitive_to:Deflexifol + Radiotherapy; sensitive_to:Fluorouracil; sensitive_to:Fluorouracil + fluoropyrimidine + folinic_acid; sensitive_to:Fluorouracil + radiotherapy; sensitive_to:Intensity Modulated Radiotherapy; sensitive_to:Leucovorin; sensitive_to:OncoSil; sensitive_to:Radiotherapy; sensitive_to:Thoracic Radiation Therapy; sensitive_to:folinic_acid; sensitive_to:radiotherapy (catype:Central nervous system cancer OR catype:Diffuse intrinsic pontine glioma OR catype:Diffuse midline glioma OR catype:Ependymoma); NOT therapy_recommendation:Deflexifol + Fluorouracil + Leucovorin:U; NOT therapy_recommendation:Deflexifol + Radiotherapy:U; NOT therapy_recommendation:Deflexifol:U; NOT therapy_recommendation:Fluorouracil:U; NOT therapy_recommendation:Leucovorin:U; NOT therapy_recommendation:Radiotherapy:U; preferential_trial_id:ACTRN12623000104651 recruitmentstates:NSW,QLD,SA,VIC,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:SA; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Prince of Wales Hospital; facility:2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital; facility:2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital; facility:3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; facility:3168 - Clayton - Monash Medical Centre; facility:4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre; facility:5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology; facility:6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre ACTRN12625001195448 catype:B-cell lymphoma; catype:B-cell malignancy; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoma; catype:Mature B-cell malignancy; catype:Non-Hodgkin's lymphoma; catype_specific:B-cell lymphoma; catype_specific:Leukaemia phase:Phase 1 recruitmentstatus:NOT_YET_RECRUITING; recruitmentstatus_active:true preferential_trial_id:ACTRN12625001195448; recruitment_status:NOT_YET_RECRUITING recruitmentstates:VIC; recruitmentstate:VIC facility:3000 - Melbourne - Peter MacCallum Cancer Centre NCT02670564 catype:Acute lymphoblastic leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoid leukaemia; catype_specific:Acute lymphoblastic leukaemia therapy:Busulfan; therapy:Treosulfan; therapy:alkylating_agent; therapy:cancer_therapy; therapy:cytotoxic_chemotherapy; ; ; phase:Phase 4 recruitmentstatus:UNKNOWN; recruitmentstatus_active:false sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dianhydrogalactitol; sensitive_to:Fotemustine; sensitive_to:Ifosfamide; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Procarbazine; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:alkylating_agent NOT therapy_recommendation:Busulfan:U; NOT therapy_recommendation:Treosulfan:U; preferential_trial_id:NCT02670564; recruitment_status:UNKNOWN recruitmentstates: NCT02724163 catype:Acute myeloid leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Myeloid leukaemia; catype_specific:Acute myeloid leukaemia therapy:Busulfan; therapy:Cyclophosphamide; therapy:Cytarabine; therapy:Daunorubicin; therapy:Fludarabine; therapy:Gemtuzumab Ozogamicin; therapy:Mitoxantrone; therapy:alkylating_agent; therapy:anthracycline; therapy:anti-CD33_antibody-drug_conjugate; therapy:antimetabolite; therapy:antineoplastic_antibiotic; therapy:cancer_therapy; therapy:cancer_therapy,CD33-targeting; therapy:cytotoxic_chemotherapy; therapy:immuno-oncology_therapy,CD33-targeting; focused_drug:Gemtuzumab Ozogamicin; focused_therapy:Gemtuzumab Ozogamicin; focused_therapy:anti-CD33_antibody-drug_conjugate; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CD33-targeting; focused_therapy:immuno-oncology_therapy,CD33-targeting; focused_therapy_class:anti-CD33_antibody-drug_conjugate phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Aldoxorubicin; sensitive_to:Amrubicin; sensitive_to:Amsacrine; sensitive_to:Azacitidine; sensitive_to:Bendamustine; sensitive_to:Berubicin; sensitive_to:Bisantrene; sensitive_to:Bleomycin; sensitive_to:Busulfan; sensitive_to:Busulfan + Cyclophosphamide; sensitive_to:Busulfan + Fludarabine; sensitive_to:Bzacitidine; sensitive_to:Capecitabine; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cladribine; sensitive_to:Cyclophosphamide; sensitive_to:Cytarabine; sensitive_to:Cytarabine + Daunorubicin; sensitive_to:Cytarabine + Fludarabine; sensitive_to:Cytarabine + Mitoxantrone; sensitive_to:Dacarbazine; sensitive_to:Dactinomycin; sensitive_to:Daunorubicin; sensitive_to:Deflexifol; sensitive_to:Dianhydrogalactitol; sensitive_to:Doxorubicin; sensitive_to:Epirubicin; sensitive_to:Fludarabine; sensitive_to:Fluorouracil; sensitive_to:Fotemustine; sensitive_to:Gemcitabine; sensitive_to:Gemtuzumab Ozogamicin; sensitive_to:Hydroxyurea; sensitive_to:IMX-110; sensitive_to:Idarubicin; sensitive_to:Ifosfamide; sensitive_to:Lometrexol; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Methotrexate; sensitive_to:Mitomycin; sensitive_to:Mitoxantrone; sensitive_to:Pegylated liposomal doxorubicin; sensitive_to:Pemetrexed; sensitive_to:Procarbazine; sensitive_to:Raltitrexed; sensitive_to:SQ3370; sensitive_to:Salinomycin; sensitive_to:Streptozotocin; sensitive_to:Tegafur; sensitive_to:Tegafur-gimeracil-oteracil potassium; sensitive_to:Temozolomide; sensitive_to:Thioguanine; sensitive_to:Thiotepa; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Trifluridine/Tipiracil; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + antimetabolite; sensitive_to:anthracycline; sensitive_to:anthracycline + antimetabolite; sensitive_to:anti-CD33_antibody-drug_conjugate; sensitive_to:antimetabolite; sensitive_to:antimetabolite + antineoplastic_antibiotic; sensitive_to:antineoplastic_antibiotic NOT therapy_recommendation:Busulfan + Cyclophosphamide:U; NOT therapy_recommendation:Busulfan + Fludarabine:U; NOT therapy_recommendation:Busulfan:U; NOT therapy_recommendation:Cyclophosphamide:U; NOT therapy_recommendation:Cytarabine + Daunorubicin:U; NOT therapy_recommendation:Cytarabine + Fludarabine:U; NOT therapy_recommendation:Cytarabine + Mitoxantrone:U; NOT therapy_recommendation:Cytarabine:U; NOT therapy_recommendation:Daunorubicin:U; NOT therapy_recommendation:Fludarabine:U; NOT therapy_recommendation:Gemtuzumab Ozogamicin:U; NOT therapy_recommendation:Mitoxantrone:U; preferential_trial_id:NCT02724163 recruitmentstates:NSW,NZ,QLD,SA,VIC,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:SA; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:2305 - New Lambton Heights - John Hunter Children's Hospital; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:3168 - Clayton - Monash Children's Hospital; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital; facility:NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre NCT03409081 catype:Acute myeloid leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Myeloid leukaemia; catype_specific:Acute myeloid leukaemia therapy:AXL/FLT3_inhibitor; therapy:AXL_inhibitor; therapy:FLT3_inhibitor; therapy:Gilteritinib; therapy:cancer_therapy; therapy:cancer_therapy,AXL-targeting; therapy:cancer_therapy,FLT3-targeting; focused_drug:Gilteritinib; focused_therapy:AXL/FLT3_inhibitor; focused_therapy:AXL_inhibitor; focused_therapy:FLT3_inhibitor; focused_therapy:Gilteritinib; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,AXL-targeting; focused_therapy:cancer_therapy,FLT3-targeting; focused_therapy_class:AXL/FLT3_inhibitor recruitmentstatus:NO_LONGER_AVAILABLE; recruitmentstatus_active:true sensitive_to:AXL/FLT3_inhibitor; sensitive_to:Gilteritinib NOT therapy_recommendation:Gilteritinib:U; preferential_trial_id:NCT03409081; recruitment_status:NO_LONGER_AVAILABLE recruitmentstates:ACT; recruitmentstate:ACT facility:2605 - Garran - The Canberra Hospital NCT03590171 catype:Acute lymphoblastic leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoid leukaemia; catype_specific:Acute lymphoblastic leukaemia therapy:Bortezomib; therapy:cancer_therapy; therapy:cancer_therapy,proteasome-targeting; therapy:proteasome_inhibitor; ; ; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Bortezomib; sensitive_to:Carfilzomib; sensitive_to:Ixazomib; sensitive_to:Marizomib; sensitive_to:proteasome_inhibitor NOT therapy_recommendation:Bortezomib:U; preferential_trial_id:NCT03590171 recruitmentstates:VIC; recruitmentstate:VIC facility:3168 - Clayton - Monash Medical Centre NCT03601442 catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoma; catype_specific:Leukaemia; catype_specific:Lymphoma therapy:CAR-T-cell_therapy; therapy:CAR-T-cell_therapy,CD19-targeting; therapy:Tisagenlecleucel; therapy:autologous_CAR-T-cell_therapy; therapy:autologous_CAR-T-cell_therapy,CD19-targeting; therapy:cancer_therapy; therapy:cancer_therapy,CD19-targeting; therapy:cell_therapy; focused_drug:Tisagenlecleucel; focused_therapy:CAR-T-cell_therapy; focused_therapy:CAR-T-cell_therapy,CD19-targeting; focused_therapy:Tisagenlecleucel; focused_therapy:autologous_CAR-T-cell_therapy; focused_therapy:autologous_CAR-T-cell_therapy,CD19-targeting; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CD19-targeting; focused_therapy:cell_therapy; focused_therapy_class:autologous_CAR-T-cell_therapy,CD19-targeting recruitmentstatus:AVAILABLE; recruitmentstatus_active:true sensitive_to:Axicabtagene Ciloleucel; sensitive_to:Brexucabtagene Autoleucel; sensitive_to:KITE-197; sensitive_to:Rapcabtagene Autoleucel; sensitive_to:Tisagenlecleucel; sensitive_to:UB-VV111; sensitive_to:WZTL002; sensitive_to:autologous_CAR-T-cell_therapy,CD19-targeting (catype:Lymphoma OR catype:Leukaemia); NOT therapy_recommendation:Tisagenlecleucel:U; preferential_trial_id:NCT03601442 recruitmentstates: NCT03838042 catype:Cancer; catype:Central nervous system cancer; catype:Neurological cancer; catype:Solid tumour; catype_specific:Central nervous system cancer; catype_specific:Solid tumour therapy:Entinostat; therapy:HDAC_inhibitor; therapy:HDAC_inhibitor,class_1_selective; therapy:Nivolumab; therapy:anti-PD-1_monoclonal_antibody; therapy:cancer_therapy; therapy:cancer_therapy,HDAC-targeting; therapy:cancer_therapy,PD-1-targeting; therapy:cancer_therapy,PD-1/PD-L1-targeting; therapy:immune_checkpoint_blockade; therapy:immune_checkpoint_blockade,PD-1-targeting; therapy:immuno-oncology_therapy,PD-1-targeting; focused_drug:Entinostat; focused_drug:Nivolumab; focused_therapy:Entinostat; focused_therapy:HDAC_inhibitor; focused_therapy:HDAC_inhibitor,class_1_selective; focused_therapy:Nivolumab; focused_therapy:anti-PD-1_monoclonal_antibody; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,HDAC-targeting; focused_therapy:cancer_therapy,PD-1-targeting; focused_therapy:cancer_therapy,PD-1/PD-L1-targeting; focused_therapy:immune_checkpoint_blockade; focused_therapy:immune_checkpoint_blockade,PD-1-targeting; focused_therapy:immuno-oncology_therapy,PD-1-targeting; focused_therapy_class:HDAC_inhibitor,class_1_selective; focused_therapy_class:anti-PD-1_monoclonal_antibody phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AI-025; sensitive_to:APL-501; sensitive_to:BAT-1306; sensitive_to:Balstilimab; sensitive_to:Budigalimab; sensitive_to:Camrelizumab; sensitive_to:Cemiplimab; sensitive_to:Cetrelimab; sensitive_to:Dostarlimab; sensitive_to:Entinostat; sensitive_to:Entinostat + Nivolumab; sensitive_to:Ezabenlimab; sensitive_to:Genolimzumab; sensitive_to:HDAC_inhibitor,class_1_selective; sensitive_to:HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody; sensitive_to:Lipustobart; sensitive_to:MEDI0680; sensitive_to:Nanatinostat; sensitive_to:Nivolumab; sensitive_to:Nofazinlimab; sensitive_to:Opucolimab; sensitive_to:Pembrolizumab; sensitive_to:Penpulimab; sensitive_to:Pimivalimab; sensitive_to:Prolgolimab; sensitive_to:Retifanlimab; sensitive_to:Rulonilimab; sensitive_to:Sasanlimab; sensitive_to:Serplulimab; sensitive_to:Sintilimab; sensitive_to:Spartalizumab; sensitive_to:Sym021; sensitive_to:Tislelizumab; sensitive_to:Toripalimab; sensitive_to:YBL006; sensitive_to:Zeluvalimab; sensitive_to:Zimberelimab; sensitive_to:anti-PD-1_monoclonal_antibody (catype:Central nervous system cancer OR catype:Solid tumour); NOT therapy_recommendation:Entinostat + Nivolumab:U; NOT therapy_recommendation:Entinostat:U; NOT therapy_recommendation:Nivolumab:U; preferential_trial_id:NCT03838042 recruitmentstates:NSW,VIC,WA; recruitmentstate:NSW; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:6009 - Perth - Perth Children's Hospital NCT03975829 catype:Anaplastic astrocytoma; catype:Anaplastic ganglioglioma; catype:Anaplastic oligodendroglioma; catype:Anaplastic pleomorphic xanthoastrocytoma; catype:Astrocytoma; catype:Benign glioma; catype:Cancer; catype:Central nervous system cancer; catype:Central neurocytoma; catype:Desmoplastic infantile astrocytoma; catype:Diffuse astrocytoma; catype:Extra-ventricular Neurocytoma; catype:Gangliocytoma; catype:Ganglioglioma; catype:Glioblastoma; catype:Glioma; catype:Glioneuronal tumour; catype:High-grade glioma; catype:Liponeurocytoma; catype:Low-grade glioma; catype:Malignant glioma; catype:Neuroblastic tumour; catype:Neurofibromatosis; catype:Neurological cancer; catype:Oligodendroglioma; catype:Papillary glioneuronal tumour; catype:Peripheral nervous system tumour; catype:Pilocytic astrocytoma; catype:Pleomorphic xanthoastrocytoma; catype:Rosette-forming glioneuronal tumour; catype:Solid tumour; catype_specific:Anaplastic astrocytoma; catype_specific:Anaplastic ganglioglioma; catype_specific:Anaplastic oligodendroglioma; catype_specific:Anaplastic pleomorphic xanthoastrocytoma; catype_specific:Astrocytoma; catype_specific:Central neurocytoma; catype_specific:Desmoplastic infantile astrocytoma; catype_specific:Diffuse astrocytoma; catype_specific:Extra-ventricular Neurocytoma; catype_specific:Gangliocytoma; catype_specific:Ganglioglioma; catype_specific:Glioblastoma; catype_specific:Glioma; catype_specific:Liponeurocytoma; catype_specific:Neurofibromatosis; catype_specific:Oligodendroglioma; catype_specific:Papillary glioneuronal tumour; catype_specific:Pilocytic astrocytoma; catype_specific:Pleomorphic xanthoastrocytoma; catype_specific:Rosette-forming glioneuronal tumour therapy:BRAF_V600_inhibitor; therapy:BRAF_inhibitor; therapy:Dabrafenib; therapy:MEK_inhibitor; therapy:RAF_inhibitor; therapy:Trametinib; therapy:cancer_therapy; therapy:cancer_therapy,BRAF-targeting; therapy:cancer_therapy,BRAF_V600-targeting; therapy:cancer_therapy,MEK-targeting; therapy:cancer_therapy,RAF-targeting; focused_drug:Dabrafenib; focused_drug:Trametinib; focused_therapy:BRAF_V600_inhibitor; focused_therapy:BRAF_inhibitor; focused_therapy:Dabrafenib; focused_therapy:MEK_inhibitor; focused_therapy:RAF_inhibitor; focused_therapy:Trametinib; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,BRAF-targeting; focused_therapy:cancer_therapy,BRAF_V600-targeting; focused_therapy:cancer_therapy,MEK-targeting; focused_therapy:cancer_therapy,RAF-targeting; focused_therapy_class:BRAF_V600_inhibitor; focused_therapy_class:MEK_inhibitor phase:Phase 4 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Agerafenib; sensitive_to:Avutometinib; sensitive_to:BRAF_V600_inhibitor; sensitive_to:BRAF_V600_inhibitor + MEK_inhibitor; sensitive_to:Binimetinib; sensitive_to:CH5126766; sensitive_to:CS3006; sensitive_to:Cobimetinib; sensitive_to:Dabrafenib; sensitive_to:Dabrafenib + Trametinib; sensitive_to:Encorafenib; sensitive_to:GDC-0623; sensitive_to:GDC-0879; sensitive_to:Luvometinib; sensitive_to:MEK_inhibitor; sensitive_to:Mirdametinib; sensitive_to:NST-628; sensitive_to:Pimasertib; sensitive_to:Polfermetinib; sensitive_to:Refametinib; sensitive_to:Selumetinib; sensitive_to:TAK-733; sensitive_to:Trametinib; sensitive_to:Vemurafenib (catype:Diffuse astrocytoma OR catype:Anaplastic astrocytoma OR catype:Astrocytoma OR catype:Oligodendroglioma OR catype:Anaplastic oligodendroglioma OR catype:Glioblastoma OR catype:Pilocytic astrocytoma OR catype:Pleomorphic xanthoastrocytoma OR catype:Anaplastic pleomorphic xanthoastrocytoma OR catype:Glioma OR catype:Gangliocytoma OR catype:Ganglioglioma OR catype:Anaplastic ganglioglioma OR catype:Desmoplastic infantile astrocytoma OR catype:Papillary glioneuronal tumour OR catype:Rosette-forming glioneuronal tumour OR catype:Central neurocytoma OR catype:Extra-ventricular Neurocytoma OR catype:Liponeurocytoma OR catype:Neurofibromatosis); NOT therapy_recommendation:Dabrafenib + Trametinib:U; NOT therapy_recommendation:Dabrafenib:U; NOT therapy_recommendation:Trametinib:U; preferential_trial_id:NCT03975829 recruitmentstates:NSW,VIC; recruitmentstate:NSW; recruitmentstate:VIC facility:2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre; facility:3052 - Parkville - Royal Children's Hospital Melbourne NCT04094610 catype:Cancer; catype:Central nervous system cancer; catype:Haematological malignancy; catype:Lymphoma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Central nervous system cancer; catype_specific:Lymphoma; catype_specific:Solid tumour therapy:ALK_inhibitor; therapy:ALK_inhibitor,third_generation; therapy:ROS1_inhibitor; therapy:Repotrectinib; therapy:TRK_inhibitor; therapy:TRK_inhibitor,second_generation; therapy:cancer_therapy; therapy:cancer_therapy,ALK-targeting; therapy:cancer_therapy,ROS1-targeting; therapy:cancer_therapy,TRK-targeting; focused_drug:Repotrectinib; focused_therapy:ALK_inhibitor; focused_therapy:ALK_inhibitor,third_generation; focused_therapy:ROS1_inhibitor; focused_therapy:Repotrectinib; focused_therapy:TRK_inhibitor; focused_therapy:TRK_inhibitor,second_generation; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,ALK-targeting; focused_therapy:cancer_therapy,ROS1-targeting; focused_therapy:cancer_therapy,TRK-targeting; focused_therapy_class:ALK_inhibitor,third_generation; focused_therapy_class:ROS1_inhibitor; focused_therapy_class:TRK_inhibitor,second_generation phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:ALK_inhibitor,third_generation; sensitive_to:APG-2449; sensitive_to:AZD3463; sensitive_to:Brigatinib; sensitive_to:Cabozantinib; sensitive_to:Ceritinib; sensitive_to:Crizotinib; sensitive_to:Ensartinib; sensitive_to:Entrectinib; sensitive_to:Foretinib; sensitive_to:IGF1R_inhibitor; sensitive_to:Lorlatinib; sensitive_to:Paltimatrectinib; sensitive_to:ROS1_inhibitor; sensitive_to:Repotrectinib; sensitive_to:Selitrectinib; sensitive_to:TRK_inhibitor,second_generation; sensitive_to:Taletrectinib; sensitive_to:Zidesamtinib; sensitive_to:Zurletrectinib (catype:Solid tumour OR catype:Lymphoma OR catype:Central nervous system cancer); NOT therapy_recommendation:Repotrectinib:U; preferential_trial_id:NCT04094610 recruitmentstates:NSW,QLD,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital NCT04293562 catype:Acute myeloid leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Myeloid leukaemia; catype_specific:Acute myeloid leukaemia therapy:AXL/FLT3_inhibitor; therapy:AXL_inhibitor; therapy:Asparaginase; therapy:Cytarabine; therapy:Daunorubicin; therapy:Dexrazoxane; therapy:Etoposide; therapy:FLT3_inhibitor; therapy:Gemtuzumab Ozogamicin; therapy:Gilteritinib; therapy:Liposome-encapsulated Daunorubicin-Cytarabine; therapy:Methotrexate; therapy:Mitoxantrone; therapy:anthracycline; therapy:anti-CD33_antibody-drug_conjugate; therapy:antifolate; therapy:antimetabolite; therapy:antineoplastic_antibiotic; therapy:cancer_therapy; therapy:cancer_therapy,AXL-targeting; therapy:cancer_therapy,CD33-targeting; therapy:cancer_therapy,FLT3-targeting; therapy:cytotoxic_chemotherapy; therapy:immuno-oncology_therapy,CD33-targeting; therapy:iron_chelator; therapy:liposomal_cytarabine/daunorubicin; therapy:topoisomerase_inhibitor; focused_drug:Gemtuzumab Ozogamicin; focused_drug:Gilteritinib; focused_drug:Liposome-encapsulated Daunorubicin-Cytarabine; focused_therapy:AXL/FLT3_inhibitor; focused_therapy:AXL_inhibitor; focused_therapy:FLT3_inhibitor; focused_therapy:Gemtuzumab Ozogamicin; focused_therapy:Gilteritinib; focused_therapy:Liposome-encapsulated Daunorubicin-Cytarabine; focused_therapy:anti-CD33_antibody-drug_conjugate; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,AXL-targeting; focused_therapy:cancer_therapy,CD33-targeting; focused_therapy:cancer_therapy,FLT3-targeting; focused_therapy:immuno-oncology_therapy,CD33-targeting; focused_therapy:liposomal_cytarabine/daunorubicin; focused_therapy_class:AXL/FLT3_inhibitor; focused_therapy_class:anti-CD33_antibody-drug_conjugate; focused_therapy_class:liposomal_cytarabine/daunorubicin phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AXL/FLT3_inhibitor; sensitive_to:AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; sensitive_to:AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + iron_chelator + topoisomerase_inhibitor; sensitive_to:AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; sensitive_to:AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + iron_chelator + topoisomerase_inhibitor; sensitive_to:AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:Aldoxorubicin; sensitive_to:Amrubicin; sensitive_to:Asparaginase; sensitive_to:Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Methotrexate + Mitoxantrone; sensitive_to:Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate; sensitive_to:Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate + Mitoxantrone; sensitive_to:Asparaginase + Cytarabine + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate + Mitoxantrone; sensitive_to:Asparaginase + Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate; sensitive_to:Asparaginase + Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate + Mitoxantrone; sensitive_to:Azacitidine; sensitive_to:Berubicin; sensitive_to:Bisantrene; sensitive_to:Bleomycin; sensitive_to:Bzacitidine; sensitive_to:Capecitabine; sensitive_to:Cladribine; sensitive_to:Cytarabine; sensitive_to:Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Methotrexate; sensitive_to:Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate; sensitive_to:Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate; sensitive_to:Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate; sensitive_to:Dactinomycin; sensitive_to:Daunorubicin; sensitive_to:Deflexifol; sensitive_to:Dexrazoxane; sensitive_to:Doxorubicin; sensitive_to:Epirubicin; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10850; sensitive_to:Fludarabine; sensitive_to:Fluorouracil; sensitive_to:Gemcitabine; sensitive_to:Gemtuzumab Ozogamicin; sensitive_to:Gilteritinib; sensitive_to:Hydroxyurea; sensitive_to:IMX-110; sensitive_to:Idarubicin; sensitive_to:Irinotecan; sensitive_to:Liposomal Irinotecan; sensitive_to:Liposome-encapsulated Daunorubicin-Cytarabine; sensitive_to:Lometrexol; sensitive_to:Methotrexate; sensitive_to:Mitomycin; sensitive_to:Mitoxantrone; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Pegylated liposomal doxorubicin; sensitive_to:Pemetrexed; sensitive_to:Raltitrexed; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:SQ3370; sensitive_to:Salinomycin; sensitive_to:Tegafur; sensitive_to:Tegafur-gimeracil-oteracil potassium; sensitive_to:Thioguanine; sensitive_to:Topotecan; sensitive_to:Trifluridine/Tipiracil; sensitive_to:anthracycline; sensitive_to:anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; sensitive_to:anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + asparaginase + iron_chelator + topoisomerase_inhibitor; sensitive_to:anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + iron_chelator + topoisomerase_inhibitor; sensitive_to:anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; sensitive_to:anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + asparaginase + iron_chelator + topoisomerase_inhibitor; sensitive_to:anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + iron_chelator + topoisomerase_inhibitor; sensitive_to:anti-CD33_antibody-drug_conjugate; sensitive_to:anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:anti-CD33_antibody-drug_conjugate + antimetabolite + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:anti-CD33_antibody-drug_conjugate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; sensitive_to:antimetabolite; sensitive_to:antineoplastic_antibiotic; sensitive_to:asparaginase; sensitive_to:iron_chelator; sensitive_to:liposomal_cytarabine/daunorubicin; sensitive_to:topoisomerase_inhibitor NOT therapy_recommendation:Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Methotrexate + Mitoxantrone:U; NOT therapy_recommendation:Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate + Mitoxantrone:U; NOT therapy_recommendation:Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate:U; NOT therapy_recommendation:Asparaginase + Cytarabine + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate + Mitoxantrone:U; NOT therapy_recommendation:Asparaginase + Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate + Mitoxantrone:U; NOT therapy_recommendation:Asparaginase + Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate:U; NOT therapy_recommendation:Asparaginase:U; NOT therapy_recommendation:Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Methotrexate:U; NOT therapy_recommendation:Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate:U; NOT therapy_recommendation:Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate:U; NOT therapy_recommendation:Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate:U; NOT therapy_recommendation:Cytarabine:U; NOT therapy_recommendation:Daunorubicin:U; NOT therapy_recommendation:Dexrazoxane:U; NOT therapy_recommendation:Etoposide:U; NOT therapy_recommendation:Gemtuzumab Ozogamicin:U; NOT therapy_recommendation:Gilteritinib:U; NOT therapy_recommendation:Liposome-encapsulated Daunorubicin-Cytarabine:U; NOT therapy_recommendation:Methotrexate:U; NOT therapy_recommendation:Mitoxantrone:U; preferential_trial_id:NCT04293562 recruitmentstates:NSW,QLD,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital NCT04323046 catype:Cancer; catype:Central nervous system cancer; catype:Glioblastoma; catype:Glioma; catype:High-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Glioblastoma; catype_specific:Glioma; catype_specific:Malignant glioma therapy:Nivolumab; therapy:anti-PD-1_monoclonal_antibody; therapy:cancer_therapy; therapy:cancer_therapy,PD-1-targeting; therapy:cancer_therapy,PD-1/PD-L1-targeting; therapy:immune_checkpoint_blockade; therapy:immune_checkpoint_blockade,PD-1-targeting; therapy:immuno-oncology_therapy,PD-1-targeting; ; ; phase:Phase 1 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AI-025; sensitive_to:APL-501; sensitive_to:BAT-1306; sensitive_to:Balstilimab; sensitive_to:Budigalimab; sensitive_to:Camrelizumab; sensitive_to:Cemiplimab; sensitive_to:Cetrelimab; sensitive_to:Dostarlimab; sensitive_to:Ezabenlimab; sensitive_to:Genolimzumab; sensitive_to:Lipustobart; sensitive_to:MEDI0680; sensitive_to:Nivolumab; sensitive_to:Nofazinlimab; sensitive_to:Opucolimab; sensitive_to:Pembrolizumab; sensitive_to:Penpulimab; sensitive_to:Pimivalimab; sensitive_to:Prolgolimab; sensitive_to:Retifanlimab; sensitive_to:Rulonilimab; sensitive_to:Sasanlimab; sensitive_to:Serplulimab; sensitive_to:Sintilimab; sensitive_to:Spartalizumab; sensitive_to:Sym021; sensitive_to:Tislelizumab; sensitive_to:Toripalimab; sensitive_to:YBL006; sensitive_to:Zeluvalimab; sensitive_to:Zimberelimab; sensitive_to:anti-PD-1_monoclonal_antibody (catype:Glioblastoma OR catype:Malignant glioma OR catype:Glioma); NOT therapy_recommendation:Nivolumab:U; preferential_trial_id:NCT04323046 recruitmentstates:NSW,QLD,SA,VIC,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:SA; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; facility:6009 - Perth - Perth Children's Hospital NCT04655404 catype:Cancer; catype:Central nervous system cancer; catype:Diffuse intrinsic pontine glioma; catype:Glioma; catype:H3K27M-mutant glioma; catype:High-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:High-grade glioma therapy:Larotrectinib; therapy:TRK_inhibitor; therapy:TRK_inhibitor,first_generation; therapy:cancer_therapy; therapy:cancer_therapy,TRK-targeting; focused_drug:Larotrectinib; focused_therapy:Larotrectinib; focused_therapy:TRK_inhibitor; focused_therapy:TRK_inhibitor,first_generation; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,TRK-targeting; focused_therapy_class:TRK_inhibitor,first_generation phase:Phase 1 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Entrectinib; sensitive_to:Larotrectinib; sensitive_to:TRK_inhibitor,first_generation (catype:High-grade glioma OR catype:Diffuse intrinsic pontine glioma); NOT therapy_recommendation:Larotrectinib:U; preferential_trial_id:NCT04655404 recruitmentstates:NSW,NZ,QLD,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital NCT04684368 catype:Cancer; catype:Central nervous system cancer; catype:Choriocarcinoma; catype:Germ cell tumour; catype:Germinoma; catype:Male genital cancers; catype:Mixed germ cell tumour; catype:Neurological cancer; catype:Non-seminoma; catype:Solid tumour; catype:Teratoma; catype:Testicular cancer; catype:Testicular embryonal carcinoma; catype:Urogenital cancer; catype:Yolk sac tumour; catype_specific:Choriocarcinoma; catype_specific:Germ cell tumour; catype_specific:Germinoma; catype_specific:Mixed germ cell tumour; catype_specific:Teratoma; catype_specific:Testicular embryonal carcinoma; catype_specific:Yolk sac tumour therapy:Carboplatin; therapy:Etoposide; therapy:Filgrastim; therapy:Ifosfamide; therapy:Mesna; therapy:Pegfilgrastim; therapy:Radiotherapy; therapy:Thiotepa; therapy:alkylating_agent; therapy:cancer_therapy; therapy:cytotoxic_chemotherapy; therapy:platinum-based_antineoplastic_agent; therapy:sodium_mercaptoethanesulfonate; therapy:topoisomerase_inhibitor; ; ; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:Carboplatin; sensitive_to:Carboplatin + Etoposide + Filgrastim + Ifosfamide + Mesna + Pegfilgrastim + Radiotherapy; sensitive_to:Carboplatin + Etoposide + Filgrastim + Ifosfamide + Mesna + Pegfilgrastim + Radiotherapy + Thiotepa; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cisplatin; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dianhydrogalactitol; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10850; sensitive_to:Filgrastim; sensitive_to:Fotemustine; sensitive_to:Ifosfamide; sensitive_to:Intensity Modulated Radiotherapy; sensitive_to:Irinotecan; sensitive_to:Liposomal Irinotecan; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Mesna; sensitive_to:OncoSil; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Oxaliplatin; sensitive_to:Pegfilgrastim; sensitive_to:Procarbazine; sensitive_to:Radiotherapy; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Thoracic Radiation Therapy; sensitive_to:Topotecan; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + radiotherapy + sodium_mercaptoethanesulfonate + topoisomerase_inhibitor; sensitive_to:granulocyte_colony_stimulating_factor; sensitive_to:platinum-based_antineoplastic_agent; sensitive_to:radiotherapy; sensitive_to:sodium_mercaptoethanesulfonate; sensitive_to:topoisomerase_inhibitor (catype:Germ cell tumour OR catype:Germinoma OR catype:Choriocarcinoma OR catype:Testicular embryonal carcinoma OR catype:Teratoma OR catype:Mixed germ cell tumour OR catype:Yolk sac tumour); NOT therapy_recommendation:Carboplatin + Etoposide + Filgrastim + Ifosfamide + Mesna + Pegfilgrastim + Radiotherapy + Thiotepa:U; NOT therapy_recommendation:Carboplatin + Etoposide + Filgrastim + Ifosfamide + Mesna + Pegfilgrastim + Radiotherapy:U; NOT therapy_recommendation:Carboplatin:U; NOT therapy_recommendation:Etoposide:U; NOT therapy_recommendation:Filgrastim:U; NOT therapy_recommendation:Ifosfamide:U; NOT therapy_recommendation:Mesna:U; NOT therapy_recommendation:Pegfilgrastim:U; NOT therapy_recommendation:Radiotherapy:U; NOT therapy_recommendation:Thiotepa:U; preferential_trial_id:NCT04684368 recruitmentstates:NSW,NZ,QLD,VIC,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre NCT04774718 catype:Cancer; catype:Central nervous system cancer; catype:Neurological cancer; catype:Solid tumour; catype_specific:Central nervous system cancer therapy:ALK/RET_inhibitor; therapy:ALK_inhibitor; therapy:ALK_inhibitor,second_generation; therapy:Alectinib; therapy:RET_inhibitor; therapy:cancer_therapy; therapy:cancer_therapy,ALK-targeting; therapy:cancer_therapy,RET-targeting; focused_drug:Alectinib; focused_therapy:ALK/RET_inhibitor; focused_therapy:ALK_inhibitor; focused_therapy:ALK_inhibitor,second_generation; focused_therapy:Alectinib; focused_therapy:RET_inhibitor; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,ALK-targeting; focused_therapy:cancer_therapy,RET-targeting; focused_therapy_class:ALK/RET_inhibitor; focused_therapy_class:ALK_inhibitor,second_generation phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:ALK/RET_inhibitor; sensitive_to:ALK_inhibitor,second_generation; sensitive_to:Alectinib; sensitive_to:Brigatinib; sensitive_to:Ceritinib NOT therapy_recommendation:Alectinib:U; preferential_trial_id:NCT04774718 recruitmentstates:NSW,VIC; recruitmentstate:NSW; recruitmentstate:VIC facility:2031 - Randwick - Sydney Children's Hospital; facility:3052 - Parkville - Royal Children's Hospital Melbourne NCT04775485 catype:Cancer; catype:Central nervous system cancer; catype:Glioma; catype:Low-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Low-grade glioma; catype_specific:Solid tumour therapy:ARAF_inhibitor; therapy:BRAF_inhibitor; therapy:CRAF_inhibitor; therapy:RAF_inhibitor; therapy:RAF_inhibitor,type_2; therapy:Tovorafenib; therapy:cancer_therapy; therapy:cancer_therapy,BRAF-targeting; therapy:cancer_therapy,CRAF-targeting; therapy:cancer_therapy,RAF-targeting; therapy:cancer_therapy,pan-RAF-targeting; therapy:pan-RAF_inhibitor; focused_drug:Tovorafenib; focused_therapy:ARAF_inhibitor; focused_therapy:BRAF_inhibitor; focused_therapy:CRAF_inhibitor; focused_therapy:RAF_inhibitor; focused_therapy:RAF_inhibitor,type_2; focused_therapy:Tovorafenib; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,BRAF-targeting; focused_therapy:cancer_therapy,CRAF-targeting; focused_therapy:cancer_therapy,RAF-targeting; focused_therapy:cancer_therapy,pan-RAF-targeting; focused_therapy:pan-RAF_inhibitor; focused_therapy_class:RAF_inhibitor,type_2 phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:BGB659; sensitive_to:LY3009120; sensitive_to:RAF_inhibitor,type_2; sensitive_to:TAK-632; sensitive_to:Tovorafenib (catype:Low-grade glioma OR catype:Solid tumour); NOT therapy_recommendation:Tovorafenib:U; preferential_trial_id:NCT04775485 recruitmentstates:NSW,QLD,VIC,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital NCT04811560 catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype_specific:Leukaemia therapy:Bleximenib; therapy:KMT2A_inhibitor; therapy:cancer_therapy; therapy:cancer_therapy,KMT2A-targeting; focused_drug:Bleximenib; focused_therapy:Bleximenib; focused_therapy:KMT2A_inhibitor; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,KMT2A-targeting; focused_therapy_class:KMT2A_inhibitor phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Bleximenib; sensitive_to:KMT2A_inhibitor NOT therapy_recommendation:Bleximenib:U; preferential_trial_id:NCT04811560 recruitmentstates:QLD,VIC,WA; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:3168 - Clayton - Monash Medical Centre; facility:4215 - Southport - Gold Coast University Hospital; facility:6000 - Perth - Royal Perth Hospital NCT04870944 catype:Cancer; catype:Central nervous system cancer; catype:Diffuse intrinsic pontine glioma; catype:Diffuse midline glioma; catype:Glioma; catype:H3K27M-mutant glioma; catype:Haematological malignancy; catype:High-grade glioma; catype:Lymphoma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Cancer; catype_specific:Central nervous system cancer; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:Diffuse midline glioma; catype_specific:Lymphoma; catype_specific:Solid tumour therapy:CBL0137; therapy:cancer_therapy; therapy:cancer_therapy,FACT_complex-targeting; therapy:curaxin,FACT_complex-targeting; focused_drug:CBL0137; focused_therapy:CBL0137; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,FACT_complex-targeting; focused_therapy:curaxin,FACT_complex-targeting; focused_therapy_class:curaxin,FACT_complex-targeting phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:CBL0137; sensitive_to:curaxin,FACT_complex-targeting (catype:Diffuse midline glioma OR catype:Cancer OR catype:Diffuse intrinsic pontine glioma OR catype:Lymphoma OR catype:Solid tumour OR catype:Central nervous system cancer); NOT therapy_recommendation:CBL0137:U; preferential_trial_id:NCT04870944 recruitmentstates:NSW; recruitmentstate:NSW facility:2031 - Randwick - Sydney Children's Hospital NCT04884035 catype:Cancer; catype:Haematological malignancy; catype:Lymphoma; catype_specific:Lymphoma therapy:CELMoD_agent; therapy:Cyclophosphamide; therapy:Doxorubicin; therapy:Golcadomide; therapy:Iberdomide; therapy:Polatuzumab vedotin; therapy:Prednisone; therapy:Rituximab; therapy:Vincristine; therapy:alkylating_agent; therapy:anthracycline; therapy:anti-CD20_monoclonal_antibody; therapy:anti-CD79b_antibody-drug_conjugate; therapy:cancer_therapy; therapy:cancer_therapy,CD20-targeting; therapy:cancer_therapy,CD79b-targeting; therapy:cancer_therapy,cereblon-targeting; therapy:cereblon_modulator; therapy:cytotoxic_chemotherapy; therapy:glucocorticoid; therapy:immuno-oncology_therapy,CD20-targeting; therapy:immuno-oncology_therapy,CD79b-targeting; therapy:vinca_alkaloid; focused_drug:Golcadomide; focused_drug:Iberdomide; focused_therapy:CELMoD_agent; focused_therapy:Golcadomide; focused_therapy:Iberdomide; focused_therapy:cancer_therapy,cereblon-targeting; focused_therapy:cereblon_modulator; focused_therapy_class:CELMoD_agent phase:Phase 1 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Aldoxorubicin; sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:CELMoD_agent; sensitive_to:CELMoD_agent + alkylating_agent + anthracycline + anti-CD20_monoclonal_antibody + anti-CD79b_antibody-drug_conjugate + glucocorticoid; sensitive_to:CELMoD_agent + alkylating_agent + anthracycline + anti-CD20_monoclonal_antibody + glucocorticoid + vinca_alkaloid; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cyclophosphamide; sensitive_to:Cyclophosphamide + Doxorubicin + Golcadomide + Polatuzumab vedotin + Prednisone + Rituximab; sensitive_to:Cyclophosphamide + Doxorubicin + Golcadomide + Prednisone + Rituximab + Vincristine; sensitive_to:Cyclophosphamide + Doxorubicin + Iberdomide + Polatuzumab vedotin + Prednisone + Rituximab; sensitive_to:Cyclophosphamide + Doxorubicin + Iberdomide + Prednisone + Rituximab + Vincristine; sensitive_to:Dacarbazine; sensitive_to:Dexamethasone; sensitive_to:Dianhydrogalactitol; sensitive_to:Doxorubicin; sensitive_to:Fotemustine; sensitive_to:Golcadomide; sensitive_to:IMX-110; sensitive_to:Iberdomide; sensitive_to:Ifosfamide; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Methylprednisolone; sensitive_to:Obinutuzumab; sensitive_to:Ofatumumab; sensitive_to:Polatuzumab vedotin; sensitive_to:Prednisolone; sensitive_to:Prednisone; sensitive_to:Procarbazine; sensitive_to:Rituximab; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Ublituximab; sensitive_to:Vinblastine; sensitive_to:Vincristine; sensitive_to:Vinflunine; sensitive_to:Vinorelbine; sensitive_to:alkylating_agent; sensitive_to:anti-CD20_monoclonal_antibody; sensitive_to:anti-CD79b_antibody-drug_conjugate; sensitive_to:doxorubicin; sensitive_to:glucocorticoid; sensitive_to:vinca_alkaloid NOT therapy_recommendation:Cyclophosphamide + Doxorubicin + Golcadomide + Polatuzumab vedotin + Prednisone + Rituximab:U; NOT therapy_recommendation:Cyclophosphamide + Doxorubicin + Golcadomide + Prednisone + Rituximab + Vincristine:U; NOT therapy_recommendation:Cyclophosphamide + Doxorubicin + Iberdomide + Polatuzumab vedotin + Prednisone + Rituximab:U; NOT therapy_recommendation:Cyclophosphamide + Doxorubicin + Iberdomide + Prednisone + Rituximab + Vincristine:U; NOT therapy_recommendation:Cyclophosphamide:U; NOT therapy_recommendation:Doxorubicin:U; NOT therapy_recommendation:Golcadomide:U; NOT therapy_recommendation:Iberdomide:U; NOT therapy_recommendation:Polatuzumab vedotin:U; NOT therapy_recommendation:Prednisone:U; NOT therapy_recommendation:Rituximab:U; NOT therapy_recommendation:Vincristine:U; preferential_trial_id:NCT04884035 recruitmentstates:NSW,SA,WA; recruitmentstate:NSW; recruitmentstate:SA; recruitmentstate:WA facility:2298 - Waratah - Calvary Mater Newcastle Medical Oncology; facility:5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre; facility:6000 - Perth - Royal Perth Hospital NCT05024929 catype:Cancer; catype:Differentiated thyroid carcinoma; catype:Endocrine gland cancer; catype:Papillary thyroid cancer; catype:Solid tumour; catype:Thyroid cancer; catype_specific:Differentiated thyroid carcinoma; catype_specific:Papillary thyroid cancer recruitmentstatus:RECRUITING; recruitmentstatus_active:true preferential_trial_id:NCT05024929 recruitmentstates:NSW; recruitmentstate:NSW facility:2145 - Westmead - The Children's Hospital at Westmead NCT05099003 catype:Cancer; catype:Central nervous system cancer; catype:Glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Malignant glioma therapy:Radiotherapy; therapy:Selinexor; therapy:XPO1_inhibitor; therapy:cancer_therapy; therapy:cancer_therapy,XPO1-targeting; focused_drug:Radiotherapy; focused_drug:Selinexor; focused_therapy:Radiotherapy; focused_therapy:Selinexor; focused_therapy:XPO1_inhibitor; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,XPO1-targeting; focused_therapy_class:XPO1_inhibitor; focused_therapy_class:radiotherapy phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Intensity Modulated Radiotherapy; sensitive_to:OncoSil; sensitive_to:Radiotherapy; sensitive_to:Radiotherapy + Selinexor; sensitive_to:Selinexor; sensitive_to:Thoracic Radiation Therapy; sensitive_to:XPO1_inhibitor; sensitive_to:XPO1_inhibitor + radiotherapy; sensitive_to:radiotherapy NOT prior_therapy:systemic_therapy; NOT therapy_recommendation:Radiotherapy + Selinexor:U; NOT therapy_recommendation:Radiotherapy:U; NOT therapy_recommendation:Selinexor:U; preferential_trial_id:NCT05099003 recruitmentstates:NSW,NZ,QLD,VIC,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital; facility:NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre NCT05183035 catype:Acute myeloid leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Myeloid leukaemia; catype_specific:Acute myeloid leukaemia therapy:Azacitidine; therapy:Bcl2_inhibitor; therapy:Cytarabine; therapy:DNA_methyltransferase_inhibitor; therapy:Fludarabine; therapy:Gemtuzumab Ozogamicin; therapy:Venetoclax; therapy:anti-CD33_antibody-drug_conjugate; therapy:antimetabolite; therapy:cancer_therapy; therapy:cancer_therapy,Bcl2-targeting; therapy:cancer_therapy,CD33-targeting; therapy:cancer_therapy,DNA_methyltransferase-targeting; therapy:cytotoxic_chemotherapy; therapy:immuno-oncology_therapy,CD33-targeting; focused_drug:Cytarabine; focused_drug:Fludarabine; focused_drug:Gemtuzumab Ozogamicin; focused_drug:Venetoclax; focused_therapy:Bcl2_inhibitor; focused_therapy:Cytarabine; focused_therapy:Fludarabine; focused_therapy:Gemtuzumab Ozogamicin; focused_therapy:Venetoclax; focused_therapy:anti-CD33_antibody-drug_conjugate; focused_therapy:antimetabolite; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,Bcl2-targeting; focused_therapy:cancer_therapy,CD33-targeting; focused_therapy:cytotoxic_chemotherapy; focused_therapy:immuno-oncology_therapy,CD33-targeting; focused_therapy_class:Bcl2_inhibitor; focused_therapy_class:anti-CD33_antibody-drug_conjugate; focused_therapy_class:antimetabolite phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:ABBV-453; sensitive_to:ABBV-623; sensitive_to:ABT-737; sensitive_to:AZD0466; sensitive_to:Asaretoclax; sensitive_to:Azacitidine; sensitive_to:Azacitidine + Cytarabine + Fludarabine + Gemtuzumab Ozogamicin + Venetoclax; sensitive_to:BGB-21447; sensitive_to:Bcl2_inhibitor; sensitive_to:Bcl2_inhibitor + DNA_methyltransferase_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite; sensitive_to:Bcl2_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite; sensitive_to:Bisantrene; sensitive_to:Bzacitidine; sensitive_to:Capecitabine; sensitive_to:Cladribine; sensitive_to:Cytarabine; sensitive_to:Deflexifol; sensitive_to:Fludarabine; sensitive_to:Fluorouracil; sensitive_to:Gemcitabine; sensitive_to:Gemtuzumab Ozogamicin; sensitive_to:Hydroxyurea; sensitive_to:LOXO-338; sensitive_to:Lisaftoclax; sensitive_to:Lometrexol; sensitive_to:Methotrexate; sensitive_to:Navitoclax; sensitive_to:Pelcitoclax; sensitive_to:Pemetrexed; sensitive_to:Raltitrexed; sensitive_to:S65487; sensitive_to:Sonrotoclax; sensitive_to:Tegafur; sensitive_to:Tegafur-gimeracil-oteracil potassium; sensitive_to:Thioguanine; sensitive_to:Trifluridine/Tipiracil; sensitive_to:Venetoclax; sensitive_to:anti-CD33_antibody-drug_conjugate; sensitive_to:antimetabolite NOT therapy_recommendation:Azacitidine + Cytarabine + Fludarabine + Gemtuzumab Ozogamicin + Venetoclax:U; NOT therapy_recommendation:Azacitidine:U; NOT therapy_recommendation:Cytarabine:U; NOT therapy_recommendation:Fludarabine:U; NOT therapy_recommendation:Gemtuzumab Ozogamicin:U; NOT therapy_recommendation:Venetoclax:U; preferential_trial_id:NCT05183035 recruitmentstates:NZ,QLD,VIC,WA; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital NCT05230758 catype:Cancer; catype:Central nervous system cancer; catype:Central nervous system primitive neuroectodermal tumour; catype:Ewing family of tumours; catype:Medulloblastoma; catype:Neurological cancer; catype:Sarcoma; catype:Solid tumour; catype_specific:Medulloblastoma therapy:Metformin; therapy:Placebo; therapy:biguanide_antihyperglycaemic_agent; therapy:cancer_therapy; focused_drug:Metformin; focused_drug:Placebo; focused_therapy:Metformin; focused_therapy:Placebo; focused_therapy:biguanide_antihyperglycaemic_agent; focused_therapy:cancer_therapy; focused_therapy_class:biguanide_antihyperglycaemic_agent; focused_therapy_class:placebo phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Metformin; sensitive_to:Placebo; sensitive_to:biguanide_antihyperglycaemic_agent; sensitive_to:placebo NOT therapy_recommendation:Metformin:U; NOT therapy_recommendation:Placebo:U; preferential_trial_id:NCT05230758 recruitmentstates:NSW,SA,VIC,WA; recruitmentstate:NSW; recruitmentstate:SA; recruitmentstate:VIC; recruitmentstate:WA facility:2145 - Westmead - The Children's Hospital at Westmead; facility:2305 - New Lambton Heights - John Hunter Children's Hospital; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:3168 - Clayton - Monash Children's Hospital; facility:5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; facility:6009 - Perth - Perth Children's Hospital NCT05269771 catype:Cancer; catype:Haematological malignancy; catype:Myeloproliferative neoplasm; catype:Polycythaemia vera; catype_specific:Polycythemia vera therapy:JAK1/JAK2_inhibitor; therapy:JAK1_inhibitor; therapy:JAK2_inhibitor; therapy:Ruxolitinib; therapy:cancer_therapy; therapy:cancer_therapy,JAK1-targeting; therapy:cancer_therapy,JAK2-targeting; focused_drug:Ruxolitinib; focused_therapy:JAK1/JAK2_inhibitor; focused_therapy:JAK1_inhibitor; focused_therapy:JAK2_inhibitor; focused_therapy:Ruxolitinib; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,JAK1-targeting; focused_therapy:cancer_therapy,JAK2-targeting; focused_therapy_class:JAK1/JAK2_inhibitor recruitmentstatus:NO_LONGER_AVAILABLE; recruitmentstatus_active:true sensitive_to:AZD1480; sensitive_to:JAK1/JAK2_inhibitor; sensitive_to:Momelotinib; sensitive_to:Ruxolitinib NOT therapy_recommendation:Ruxolitinib:U; preferential_trial_id:NCT05269771; recruitment_status:NO_LONGER_AVAILABLE recruitmentstates:NSW; recruitmentstate:NSW facility:2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit NCT05304585 catype:Alveolar rhabdomyosarcoma; catype:Cancer; catype:Embryonal rhabdomyosarcoma; catype:Rhabdomyosarcoma; catype:Sarcoma; catype:Sclerosing rhabdomyosarcoma; catype:Soft tissue sarcoma; catype:Solid tumour; catype_specific:Alveolar rhabdomyosarcoma; catype_specific:Embryonal rhabdomyosarcoma; catype_specific:Sclerosing rhabdomyosarcoma therapy:Cyclophosphamide; therapy:Dactinomycin; therapy:Radiotherapy; therapy:Vincristine; therapy:alkylating_agent; therapy:antineoplastic_antibiotic; therapy:cancer_therapy; therapy:cytotoxic_chemotherapy; therapy:vinca_alkaloid; ; ; phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Bleomycin; sensitive_to:Busulfan; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cyclophosphamide; sensitive_to:Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; sensitive_to:Dacarbazine; sensitive_to:Dactinomycin; sensitive_to:Dactinomycin + Vincristine; sensitive_to:Dianhydrogalactitol; sensitive_to:Fotemustine; sensitive_to:Ifosfamide; sensitive_to:Intensity Modulated Radiotherapy; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Mitomycin; sensitive_to:Mitoxantrone; sensitive_to:OncoSil; sensitive_to:Procarbazine; sensitive_to:Radiotherapy; sensitive_to:Salinomycin; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Thoracic Radiation Therapy; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Vinblastine; sensitive_to:Vincristine; sensitive_to:Vinflunine; sensitive_to:Vinorelbine; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; sensitive_to:antineoplastic_antibiotic; sensitive_to:antineoplastic_antibiotic + vinca_alkaloid; sensitive_to:radiotherapy; sensitive_to:vinca_alkaloid (catype:Embryonal rhabdomyosarcoma OR catype:Alveolar rhabdomyosarcoma OR catype:Sclerosing rhabdomyosarcoma); NOT therapy_recommendation:Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine:U; NOT therapy_recommendation:Cyclophosphamide:U; NOT therapy_recommendation:Dactinomycin + Vincristine:U; NOT therapy_recommendation:Dactinomycin:U; NOT therapy_recommendation:Radiotherapy:U; NOT therapy_recommendation:Vincristine:U; preferential_trial_id:NCT05304585 recruitmentstates:NSW,NZ,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital; facility:NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre NCT05327894 catype:Acute lymphoblastic leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoid leukaemia; catype:Mixed phenotype acute leukaemia; catype_specific:Acute lymphoblastic leukaemia; catype_specific:Mixed phenotype acute leukaemia therapy:Blinatumomab; therapy:Prednisone; therapy:bispecific_T-cell_engager,CD19-targeting; therapy:cancer_therapy; therapy:cancer_therapy,CD19-targeting; therapy:glucocorticoid; therapy:immuno-oncology_therapy,CD19-targeting; therapy:therapeutic_modality,bispecific_T-cell_engager; therapy:therapeutic_modality,bispecific_antibody; ; ; phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Blinatumomab; sensitive_to:Blinatumomab + Prednisone; sensitive_to:Dexamethasone; sensitive_to:Methylprednisolone; sensitive_to:Prednisolone; sensitive_to:Prednisone; sensitive_to:Surovatamig; sensitive_to:bispecific_T-cell_engager,CD19-targeting; sensitive_to:bispecific_T-cell_engager,CD19-targeting + glucocorticoid; sensitive_to:glucocorticoid (catype:Acute lymphoblastic leukaemia OR catype:Mixed phenotype acute leukaemia); NOT therapy_recommendation:Blinatumomab + Prednisone:U; NOT therapy_recommendation:Blinatumomab:U; NOT therapy_recommendation:Prednisone:U; preferential_trial_id:NCT05327894 recruitmentstates:NSW,NZ,QLD,SA,VIC,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:SA; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:2305 - New Lambton Heights - John Hunter Children's Hospital; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:3168 - Clayton - Monash Children's Hospital; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.8011 - Christchurch - Christchurch Children's Hospital NCT05504291 catype:Cancer; catype:Retinoblastoma; catype:Sarcoma; catype:Solid tumour; catype_specific:Retinoblastoma therapy:Carboplatin; therapy:Etoposide; therapy:Melphalan; therapy:Vincristine; therapy:alkylating_agent; therapy:cancer_therapy; therapy:cytotoxic_chemotherapy; therapy:platinum-based_antineoplastic_agent; therapy:topoisomerase_inhibitor; therapy:vinca_alkaloid; focused_drug:Melphalan; focused_therapy:Melphalan; focused_therapy:alkylating_agent; focused_therapy:cancer_therapy; focused_therapy:cytotoxic_chemotherapy; focused_therapy_class:alkylating_agent phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:Carboplatin; sensitive_to:Carboplatin + Etoposide + Melphalan + Vincristine; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cisplatin; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dianhydrogalactitol; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10850; sensitive_to:Fotemustine; sensitive_to:Ifosfamide; sensitive_to:Irinotecan; sensitive_to:Liposomal Irinotecan; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Oxaliplatin; sensitive_to:Procarbazine; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Topotecan; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Vinblastine; sensitive_to:Vincristine; sensitive_to:Vinflunine; sensitive_to:Vinorelbine; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; sensitive_to:platinum-based_antineoplastic_agent; sensitive_to:topoisomerase_inhibitor; sensitive_to:vinca_alkaloid NOT therapy_recommendation:Carboplatin + Etoposide + Melphalan + Vincristine:U; NOT therapy_recommendation:Carboplatin:U; NOT therapy_recommendation:Etoposide:U; NOT therapy_recommendation:Melphalan:U; NOT therapy_recommendation:Vincristine:U; preferential_trial_id:NCT05504291 recruitmentstates:VIC,WA; recruitmentstate:VIC; recruitmentstate:WA facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:6009 - Perth - Perth Children's Hospital NCT05533775 catype:Cancer; catype:Haematological malignancy; catype:Lymphoma; catype:Non-Hodgkin's lymphoma; catype_specific:Non-Hodgkin's lymphoma therapy:Carboplatin; therapy:Etoposide; therapy:Glofitamab; therapy:Ifosfamide; therapy:Obinutuzumab; therapy:Rituximab; therapy:Tocilizumab; therapy:alkylating_agent; therapy:anti-CD20_monoclonal_antibody; therapy:anti-IL-6_monoclonal_antibody; therapy:bispecific_T-cell_engager,CD20-targeting; therapy:cancer_therapy; therapy:cancer_therapy,CD20-targeting; therapy:cancer_therapy,IL-6-targeting; therapy:cytotoxic_chemotherapy; therapy:immuno-oncology_therapy,CD20-targeting; therapy:immuno-oncology_therapy,IL-6-targeting; therapy:platinum-based_antineoplastic_agent; therapy:therapeutic_modality,bispecific_T-cell_engager; therapy:therapeutic_modality,bispecific_antibody; therapy:topoisomerase_inhibitor; focused_drug:Glofitamab; focused_therapy:Glofitamab; focused_therapy:bispecific_T-cell_engager,CD20-targeting; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CD20-targeting; focused_therapy:immuno-oncology_therapy,CD20-targeting; focused_therapy:therapeutic_modality,bispecific_T-cell_engager; focused_therapy:therapeutic_modality,bispecific_antibody; focused_therapy_class:bispecific_T-cell_engager,CD20-targeting phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AZD5492; sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:Carboplatin; sensitive_to:Carboplatin + Etoposide + Glofitamab + Ifosfamide + Obinutuzumab + Rituximab + Tocilizumab; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cisplatin; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dianhydrogalactitol; sensitive_to:Epcoritamab; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10850; sensitive_to:Fotemustine; sensitive_to:GB261; sensitive_to:Glofitamab; sensitive_to:Glofitamab + Obinutuzumab + Tocilizumab; sensitive_to:Ifosfamide; sensitive_to:Imvotamab; sensitive_to:Irinotecan; sensitive_to:Liposomal Irinotecan; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Mosunetuzumab; sensitive_to:Obinutuzumab; sensitive_to:Odronextamab; sensitive_to:Ofatumumab; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Oxaliplatin; sensitive_to:Procarbazine; sensitive_to:Rituximab; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Tocilizumab; sensitive_to:Topotecan; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Ublituximab; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + anti-CD20_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; sensitive_to:anti-CD20_monoclonal_antibody; sensitive_to:anti-CD20_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting; sensitive_to:anti-IL-6_monoclonal_antibody; sensitive_to:bispecific_T-cell_engager,CD20-targeting; sensitive_to:platinum-based_antineoplastic_agent; sensitive_to:topoisomerase_inhibitor NOT therapy_recommendation:Carboplatin + Etoposide + Glofitamab + Ifosfamide + Obinutuzumab + Rituximab + Tocilizumab:U; NOT therapy_recommendation:Carboplatin:U; NOT therapy_recommendation:Etoposide:U; NOT therapy_recommendation:Glofitamab + Obinutuzumab + Tocilizumab:U; NOT therapy_recommendation:Glofitamab:U; NOT therapy_recommendation:Ifosfamide:U; NOT therapy_recommendation:Obinutuzumab:U; NOT therapy_recommendation:Rituximab:U; NOT therapy_recommendation:Tocilizumab:U; preferential_trial_id:NCT05533775 recruitmentstates:QLD,WA; recruitmentstate:QLD; recruitmentstate:WA facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital NCT05839379 catype:Anaplastic astrocytoma; catype:Cancer; catype:Central nervous system cancer; catype:Diffuse intrinsic pontine glioma; catype:Glioblastoma; catype:Glioma; catype:H3K27M-mutant glioma; catype:High-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Anaplastic astrocytoma; catype_specific:Central nervous system cancer; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:Glioblastoma; catype_specific:Glioma; catype_specific:H3K27M-mutant glioma; catype_specific:High-grade glioma recruitmentstatus:RECRUITING; recruitmentstatus_active:true preferential_trial_id:NCT05839379 recruitmentstates:NSW,NZ,QLD,VIC,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital NCT05843253 catype:Anaplastic astrocytoma; catype:Cancer; catype:Central nervous system cancer; catype:Diffuse hemispheric glioma; catype:Diffuse intrinsic pontine glioma; catype:Glioblastoma; catype:Glioma; catype:H3K27M-mutant glioma; catype:High-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Anaplastic astrocytoma; catype_specific:Central nervous system cancer; catype_specific:Diffuse hemispheric glioma; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:Glioblastoma; catype_specific:Glioma; catype_specific:H3K27M-mutant glioma; catype_specific:High-grade glioma therapy:CDK4/6_inhibitor; therapy:CDK4_inhibitor; therapy:CDK6_inhibitor; therapy:Everolimus; therapy:Radiotherapy; therapy:Ribociclib; therapy:Temozolomide; therapy:alkylating_agent; therapy:cancer_therapy; therapy:cancer_therapy,CDK4-targeting; therapy:cancer_therapy,CDK6-targeting; therapy:cancer_therapy,mTOR-targeting; therapy:cancer_therapy,mTORC1-targeting; therapy:cytotoxic_chemotherapy; therapy:mTORC1_inhibitor; therapy:mTOR_inhibitor; focused_drug:Everolimus; focused_drug:Radiotherapy; focused_drug:Ribociclib; focused_drug:Temozolomide; focused_therapy:CDK4/6_inhibitor; focused_therapy:CDK4_inhibitor; focused_therapy:CDK6_inhibitor; focused_therapy:Everolimus; focused_therapy:Radiotherapy; focused_therapy:Ribociclib; focused_therapy:Temozolomide; focused_therapy:alkylating_agent; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CDK4-targeting; focused_therapy:cancer_therapy,CDK6-targeting; focused_therapy:cancer_therapy,mTOR-targeting; focused_therapy:cancer_therapy,mTORC1-targeting; focused_therapy:cytotoxic_chemotherapy; focused_therapy:mTORC1_inhibitor; focused_therapy:mTOR_inhibitor; focused_therapy_class:CDK4/6_inhibitor; focused_therapy_class:alkylating_agent; focused_therapy_class:mTORC1_inhibitor; focused_therapy_class:radiotherapy phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AZD8055; sensitive_to:Abemaciclib; sensitive_to:Amsacrine; sensitive_to:Auceliciclib; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:CDK4/6_inhibitor; sensitive_to:CDK4/6_inhibitor + alkylating_agent; sensitive_to:CDK4/6_inhibitor + mTORC1_inhibitor; sensitive_to:CS3002; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dalpiciclib; sensitive_to:Dianhydrogalactitol; sensitive_to:Everolimus; sensitive_to:Everolimus + Ribociclib; sensitive_to:FN-1501; sensitive_to:Fotemustine; sensitive_to:GDC-4198; sensitive_to:Gedatolisib; sensitive_to:Ifosfamide; sensitive_to:Intensity Modulated Radiotherapy; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:OncoSil; sensitive_to:Palbociclib; sensitive_to:Paxalisib; sensitive_to:Procarbazine; sensitive_to:RMC-5552; sensitive_to:RMC-6272; sensitive_to:Radiotherapy; sensitive_to:Ribociclib; sensitive_to:Ribociclib + Temozolomide; sensitive_to:Sapanisertib; sensitive_to:Sapu003; sensitive_to:Sirolimus; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Temsirolimus; sensitive_to:Thiotepa; sensitive_to:Thoracic Radiation Therapy; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Trilaciclib; sensitive_to:Vistusertib; sensitive_to:alkylating_agent; sensitive_to:mTORC1_inhibitor; sensitive_to:radiotherapy (catype:High-grade glioma OR catype:Diffuse intrinsic pontine glioma OR catype:Anaplastic astrocytoma OR catype:Glioblastoma OR catype:H3K27M-mutant glioma OR catype:Central nervous system cancer OR catype:Glioma OR catype:Diffuse hemispheric glioma); NOT therapy_recommendation:Everolimus + Ribociclib:U; NOT therapy_recommendation:Everolimus:U; NOT therapy_recommendation:Radiotherapy:U; NOT therapy_recommendation:Ribociclib + Temozolomide:U; NOT therapy_recommendation:Ribociclib:U; NOT therapy_recommendation:Temozolomide:U; preferential_trial_id:NCT05843253 recruitmentstates:NSW,NZ,QLD,VIC,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital NCT05991388 catype:Cancer; catype:Haematological malignancy; catype:Lymphoma; catype:Non-Hodgkin's lymphoma; catype_specific:Non-Hodgkin's lymphoma therapy:Carboplatin; therapy:Dexamethasone; therapy:Etoposide; therapy:Ifosfamide; therapy:Loncastuximab Tesirine; therapy:Odronextamab; therapy:Rituximab; therapy:alkylating_agent; therapy:anti-CD19_antibody-drug_conjugate; therapy:anti-CD20_monoclonal_antibody; therapy:bispecific_T-cell_engager,CD20-targeting; therapy:cancer_therapy; therapy:cancer_therapy,CD19-targeting; therapy:cancer_therapy,CD20-targeting; therapy:cytotoxic_chemotherapy; therapy:glucocorticoid; therapy:immuno-oncology_therapy,CD19-targeting; therapy:immuno-oncology_therapy,CD20-targeting; therapy:platinum-based_antineoplastic_agent; therapy:therapeutic_modality,bispecific_T-cell_engager; therapy:therapeutic_modality,bispecific_antibody; therapy:topoisomerase_inhibitor; ; ; phase:Phase 2; phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AZD5492; sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:Carboplatin; sensitive_to:Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Loncastuximab Tesirine + Rituximab; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cisplatin; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dexamethasone; sensitive_to:Dianhydrogalactitol; sensitive_to:Epcoritamab; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10850; sensitive_to:Fotemustine; sensitive_to:GB261; sensitive_to:Glofitamab; sensitive_to:IKS03; sensitive_to:Ifosfamide; sensitive_to:Imvotamab; sensitive_to:Irinotecan; sensitive_to:Liposomal Irinotecan; sensitive_to:Lomustine; sensitive_to:Loncastuximab Tesirine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Methylprednisolone; sensitive_to:Mosunetuzumab; sensitive_to:Obinutuzumab; sensitive_to:Odronextamab; sensitive_to:Ofatumumab; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Oxaliplatin; sensitive_to:Prednisolone; sensitive_to:Prednisone; sensitive_to:Procarbazine; sensitive_to:Rituximab; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Topotecan; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Ublituximab; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + anti-CD19_antibody-drug_conjugate + anti-CD20_monoclonal_antibody + glucocorticoid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; sensitive_to:anti-CD19_antibody-drug_conjugate; sensitive_to:anti-CD20_monoclonal_antibody; sensitive_to:bispecific_T-cell_engager,CD20-targeting; sensitive_to:glucocorticoid; sensitive_to:platinum-based_antineoplastic_agent; sensitive_to:topoisomerase_inhibitor NOT therapy_recommendation:Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Loncastuximab Tesirine + Rituximab:U; NOT therapy_recommendation:Carboplatin:U; NOT therapy_recommendation:Dexamethasone:U; NOT therapy_recommendation:Etoposide:U; NOT therapy_recommendation:Ifosfamide:U; NOT therapy_recommendation:Loncastuximab Tesirine:U; NOT therapy_recommendation:Odronextamab:U; NOT therapy_recommendation:Rituximab:U; preferential_trial_id:NCT05991388 recruitmentstates:NSW,NZ,QLD,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:WA facility:2145 - Westmead - The Children's Hospital at Westmead; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital NCT05999994 catype:Cancer; catype_specific:Cancer therapy:Abemaciclib; therapy:CDK4/6_inhibitor; therapy:CDK4_inhibitor; therapy:CDK6_inhibitor; therapy:Cyclophosphamide; therapy:Docetaxel; therapy:Gemcitabine; therapy:Irinotecan; therapy:Ramucirumab; therapy:Temozolomide; therapy:Vinorelbine; therapy:alkylating_agent; therapy:anti-VEGFR2_monoclonal_antibody; therapy:antimetabolite; therapy:cancer_therapy; therapy:cancer_therapy,CDK4-targeting; therapy:cancer_therapy,CDK6-targeting; therapy:cancer_therapy,VEGFR2-targeting; therapy:cytotoxic_chemotherapy; therapy:immuno-oncology_therapy,VEGFR2-targeting; therapy:taxane; therapy:topoisomerase_inhibitor; therapy:vinca_alkaloid; ; ; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Abemaciclib; sensitive_to:Abemaciclib + Irinotecan + Temozolomide; sensitive_to:Amsacrine; sensitive_to:Auceliciclib; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:CDK4/6_inhibitor; sensitive_to:CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; sensitive_to:CS3002; sensitive_to:Cabazitaxel; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cyclophosphamide; sensitive_to:Cyclophosphamide + Ramucirumab + Vinorelbine; sensitive_to:Cyclophosphamide + Vinorelbine; sensitive_to:Dacarbazine; sensitive_to:Dalpiciclib; sensitive_to:Dianhydrogalactitol; sensitive_to:Docetaxel; sensitive_to:Docetaxel + Gemcitabine; sensitive_to:Docetaxel + Gemcitabine + Ramucirumab; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10832; sensitive_to:FF-10850; sensitive_to:FN-1501; sensitive_to:Fosgemcitabine Palabenamide; sensitive_to:Fotemustine; sensitive_to:GDC-4198; sensitive_to:Gemcitabine; sensitive_to:Ifosfamide; sensitive_to:Irinotecan; sensitive_to:Irinotecan + Temozolomide; sensitive_to:Liposomal Irinotecan; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:MSB0254; sensitive_to:Melphalan; sensitive_to:Nab-paclitaxel; sensitive_to:Olinvacimab; sensitive_to:Oral Docetaxel; sensitive_to:Oratecan; sensitive_to:Oraxol; sensitive_to:Orotecan; sensitive_to:Paclitaxel; sensitive_to:Palbociclib; sensitive_to:Procarbazine; sensitive_to:Ramucirumab; sensitive_to:Ribociclib; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Tesetaxel; sensitive_to:Thiotepa; sensitive_to:Topotecan; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Trilaciclib; sensitive_to:Vinblastine; sensitive_to:Vincristine; sensitive_to:Vinflunine; sensitive_to:Vinorelbine; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + anti-VEGFR2_monoclonal_antibody + vinca_alkaloid; sensitive_to:alkylating_agent + topoisomerase_inhibitor; sensitive_to:alkylating_agent + vinca_alkaloid; sensitive_to:anti-VEGFR2_monoclonal_antibody; sensitive_to:anti-VEGFR2_monoclonal_antibody + antimetabolite + taxane; sensitive_to:antimetabolite + taxane; sensitive_to:gemcitabine; sensitive_to:taxane; sensitive_to:topoisomerase_inhibitor; sensitive_to:vinca_alkaloid NOT therapy_recommendation:Abemaciclib + Irinotecan + Temozolomide:U; NOT therapy_recommendation:Abemaciclib:U; NOT therapy_recommendation:Cyclophosphamide + Ramucirumab + Vinorelbine:U; NOT therapy_recommendation:Cyclophosphamide + Vinorelbine:U; NOT therapy_recommendation:Cyclophosphamide:U; NOT therapy_recommendation:Docetaxel + Gemcitabine + Ramucirumab:U; NOT therapy_recommendation:Docetaxel + Gemcitabine:U; NOT therapy_recommendation:Docetaxel:U; NOT therapy_recommendation:Gemcitabine:U; NOT therapy_recommendation:Irinotecan + Temozolomide:U; NOT therapy_recommendation:Irinotecan:U; NOT therapy_recommendation:Ramucirumab:U; NOT therapy_recommendation:Temozolomide:U; NOT therapy_recommendation:Vinorelbine:U; preferential_trial_id:NCT05999994 recruitmentstates:NSW,VIC; recruitmentstate:NSW; recruitmentstate:VIC facility:2050 - Camperdown - Chris O'Brien Lifehouse; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:3000 - Melbourne - Peter MacCallum Cancer Centre; facility:3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health NCT06124157 catype:Acute lymphoblastic leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoid leukaemia; catype_specific:Acute lymphoblastic leukaemia therapy:Asparaginase; therapy:BCR-ABL1_inhibitor; therapy:BCR-ABL1_inhibitor,first_generation; therapy:BCR-ABL1_inhibitor,second_generation; therapy:Blinatumomab; therapy:Cyclophosphamide; therapy:Cytarabine; therapy:Dasatinib; therapy:Daunorubicin; therapy:Doxorubicin; therapy:Imatinib; therapy:KIT_inhibitor; therapy:Leucovorin; therapy:Methotrexate; therapy:PDGFRA_inhibitor; therapy:Prednisolone; therapy:Prednisone; therapy:Radiotherapy; therapy:SRC_inhibitor; therapy:Thioguanine; therapy:Vincristine; therapy:YES1_inhibitor; therapy:alkylating_agent; therapy:anthracycline; therapy:antifolate; therapy:antimetabolite; therapy:bispecific_T-cell_engager,CD19-targeting; therapy:cancer_therapy; therapy:cancer_therapy,BCR-ABL1-targeting; therapy:cancer_therapy,CD19-targeting; therapy:cancer_therapy,KIT-targeting; therapy:cancer_therapy,PDGFRA-targeting; therapy:cancer_therapy,SRC-targeting; therapy:cancer_therapy,YES1-targeting; therapy:cytotoxic_chemotherapy; therapy:glucocorticoid; therapy:immuno-oncology_therapy,CD19-targeting; therapy:therapeutic_modality,bispecific_T-cell_engager; therapy:therapeutic_modality,bispecific_antibody; therapy:vinca_alkaloid; focused_drug:Blinatumomab; focused_therapy:Blinatumomab; focused_therapy:bispecific_T-cell_engager,CD19-targeting; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CD19-targeting; focused_therapy:immuno-oncology_therapy,CD19-targeting; focused_therapy:therapeutic_modality,bispecific_T-cell_engager; focused_therapy:therapeutic_modality,bispecific_antibody; focused_therapy_class:bispecific_T-cell_engager,CD19-targeting phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Aldoxorubicin; sensitive_to:Amrubicin; sensitive_to:Amsacrine; sensitive_to:Amuvatinib; sensitive_to:Arfolitixorin; sensitive_to:Asparaginase; sensitive_to:Avapritinib; sensitive_to:Axitinib; sensitive_to:Azacitidine; sensitive_to:BCR-ABL1_inhibitor,first_generation; sensitive_to:BCR-ABL1_inhibitor,first_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:BCR-ABL1_inhibitor,first_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:BCR-ABL1_inhibitor,second_generation; sensitive_to:BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:Bendamustine; sensitive_to:Berubicin; sensitive_to:Bezuclastinib; sensitive_to:Bisantrene; sensitive_to:Blinatumomab; sensitive_to:Blinatumomab + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Doxorubicin + Leucovorin + Methotrexate + Prednisolone + Prednisone + Radiotherapy + Thioguanine + Vincristine; sensitive_to:Blinatumomab + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Doxorubicin + Leucovorin + Methotrexate + Prednisolone + Prednisone + Thioguanine + Vincristine; sensitive_to:Blinatumomab + Cyclophosphamide + Cytarabine + Daunorubicin + Doxorubicin + Imatinib + Leucovorin + Methotrexate + Prednisolone + Prednisone + Radiotherapy + Thioguanine + Vincristine; sensitive_to:Bosutinib; sensitive_to:Busulfan; sensitive_to:Bzacitidine; sensitive_to:Cabozantinib; sensitive_to:Capecitabine; sensitive_to:Carmustine; sensitive_to:Catequentinib; sensitive_to:Chiauranib; sensitive_to:Chlorambucil; sensitive_to:Cladribine; sensitive_to:Crenolanib; sensitive_to:Cyclophosphamide; sensitive_to:Cytarabine; sensitive_to:Dacarbazine; sensitive_to:Dasatinib; sensitive_to:Daunorubicin; sensitive_to:Deflexifol; sensitive_to:Dexamethasone; sensitive_to:Dianhydrogalactitol; sensitive_to:Doxorubicin; sensitive_to:Elenestinib; sensitive_to:Elzovantinib; sensitive_to:Enbezotinib; sensitive_to:Epirubicin; sensitive_to:Famitinib; sensitive_to:Fludarabine; sensitive_to:Fluorouracil; sensitive_to:Fotemustine; sensitive_to:Gemcitabine; sensitive_to:Hydroxyurea; sensitive_to:IMX-110; sensitive_to:Idarubicin; sensitive_to:Ifosfamide; sensitive_to:Imatinib; sensitive_to:Intensity Modulated Radiotherapy; sensitive_to:KIT_inhibitor; sensitive_to:KIT_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:KIT_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:KIT_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:KIT_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:Leucovorin; sensitive_to:Lometrexol; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:M4205; sensitive_to:Melphalan; sensitive_to:Methotrexate; sensitive_to:Methylprednisolone; sensitive_to:Midostaurin; sensitive_to:Nilotinib; sensitive_to:Nintedanib; sensitive_to:OncoSil; sensitive_to:PDGFRA_inhibitor; sensitive_to:PDGFRA_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:PDGFRA_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:PDGFRA_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:PDGFRA_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:Pazopanib; sensitive_to:Pegylated liposomal doxorubicin; sensitive_to:Pemetrexed; sensitive_to:Pexidartinib; sensitive_to:Prednisolone; sensitive_to:Prednisone; sensitive_to:Procarbazine; sensitive_to:Quizartinib; sensitive_to:Radiotherapy; sensitive_to:Raltitrexed; sensitive_to:Regorafenib; sensitive_to:Ripretinib; sensitive_to:SQ3370; sensitive_to:SRC_inhibitor; sensitive_to:SRC_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:SRC_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:SRC_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:SRC_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:Sitravatinib; sensitive_to:Sorafenib; sensitive_to:Streptozotocin; sensitive_to:Sunitinib; sensitive_to:Surovatamig; sensitive_to:Tandutinib; sensitive_to:Tegafur; sensitive_to:Tegafur-gimeracil-oteracil potassium; sensitive_to:Temozolomide; sensitive_to:Thioguanine; sensitive_to:Thiotepa; sensitive_to:Thoracic Radiation Therapy; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Trifluridine/Tipiracil; sensitive_to:Vinblastine; sensitive_to:Vincristine; sensitive_to:Vinflunine; sensitive_to:Vinorelbine; sensitive_to:YES1_inhibitor; sensitive_to:YES1_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:YES1_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:YES1_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; sensitive_to:YES1_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; sensitive_to:alkylating_agent; sensitive_to:anthracycline; sensitive_to:antimetabolite; sensitive_to:asparaginase; sensitive_to:bispecific_T-cell_engager,CD19-targeting; sensitive_to:doxorubicin; sensitive_to:folinic_acid; sensitive_to:glucocorticoid; sensitive_to:radiotherapy; sensitive_to:vinca_alkaloid NOT therapy_recommendation:Asparaginase:U; NOT therapy_recommendation:Blinatumomab + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Doxorubicin + Leucovorin + Methotrexate + Prednisolone + Prednisone + Radiotherapy + Thioguanine + Vincristine:U; NOT therapy_recommendation:Blinatumomab + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Doxorubicin + Leucovorin + Methotrexate + Prednisolone + Prednisone + Thioguanine + Vincristine:U; NOT therapy_recommendation:Blinatumomab + Cyclophosphamide + Cytarabine + Daunorubicin + Doxorubicin + Imatinib + Leucovorin + Methotrexate + Prednisolone + Prednisone + Radiotherapy + Thioguanine + Vincristine:U; NOT therapy_recommendation:Blinatumomab:U; NOT therapy_recommendation:Cyclophosphamide:U; NOT therapy_recommendation:Cytarabine:U; NOT therapy_recommendation:Dasatinib:U; NOT therapy_recommendation:Daunorubicin:U; NOT therapy_recommendation:Doxorubicin:U; NOT therapy_recommendation:Imatinib:U; NOT therapy_recommendation:Leucovorin:U; NOT therapy_recommendation:Methotrexate:U; NOT therapy_recommendation:Prednisolone:U; NOT therapy_recommendation:Prednisone:U; NOT therapy_recommendation:Radiotherapy:U; NOT therapy_recommendation:Thioguanine:U; NOT therapy_recommendation:Vincristine:U; preferential_trial_id:NCT06124157 recruitmentstates:QLD,WA; recruitmentstate:QLD; recruitmentstate:WA facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital NCT06137118 catype:Acute lymphoblastic leukaemia; catype:B-cell acute lymphoblastic leukaemia/lymphoma; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoid leukaemia; catype_specific:B-cell acute lymphoblastic leukaemia/lymphoma therapy:Surovatamig; therapy:bispecific_T-cell_engager,CD19-targeting; therapy:cancer_therapy; therapy:cancer_therapy,CD19-targeting; therapy:immuno-oncology_therapy,CD19-targeting; therapy:therapeutic_modality,bispecific_T-cell_engager; therapy:therapeutic_modality,bispecific_antibody; focused_drug:Surovatamig; focused_therapy:Surovatamig; focused_therapy:bispecific_T-cell_engager,CD19-targeting; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CD19-targeting; focused_therapy:immuno-oncology_therapy,CD19-targeting; focused_therapy:therapeutic_modality,bispecific_T-cell_engager; focused_therapy:therapeutic_modality,bispecific_antibody; focused_therapy_class:bispecific_T-cell_engager,CD19-targeting phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Blinatumomab; sensitive_to:Surovatamig; sensitive_to:bispecific_T-cell_engager,CD19-targeting NOT therapy_recommendation:Surovatamig:U; preferential_trial_id:NCT06137118 recruitmentstates:VIC; recruitmentstate:VIC facility:3000 - Melbourne - Peter MacCallum Cancer Centre NCT06137144 catype:Cancer; catype:Haematological malignancy; catype:Lymphoma; catype:Non-Hodgkin's lymphoma; catype:Peripheral T-cell lymphoma; catype:T-cell lymphoma; catype_specific:Lymphoma; catype_specific:Non-Hodgkin's lymphoma; catype_specific:Peripheral T-cell lymphoma therapy:AZD3470; therapy:PRMT5_inhibitor; therapy:PRMT5_inhibitor,MTA-co-operative; therapy:PRMT_inhibitor; therapy:Pembrolizumab; therapy:anti-PD-1_monoclonal_antibody; therapy:cancer_therapy; therapy:cancer_therapy,PD-1-targeting; therapy:cancer_therapy,PD-1/PD-L1-targeting; therapy:cancer_therapy,PRMT5-targeting; therapy:immune_checkpoint_blockade; therapy:immune_checkpoint_blockade,PD-1-targeting; therapy:immuno-oncology_therapy,PD-1-targeting; therapy:type_2_PRMT_inhibitor; focused_drug:AZD3470; focused_therapy:AZD3470; focused_therapy:PRMT5_inhibitor; focused_therapy:PRMT5_inhibitor,MTA-co-operative; focused_therapy:PRMT_inhibitor; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,PRMT5-targeting; focused_therapy:type_2_PRMT_inhibitor; focused_therapy_class:PRMT5_inhibitor; focused_therapy_class:PRMT5_inhibitor,MTA-co-operative phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AI-025; sensitive_to:APL-501; sensitive_to:AZD3470; sensitive_to:AZD3470 + Pembrolizumab; sensitive_to:Anvumetostat; sensitive_to:BAT-1306; sensitive_to:BAY 3713372; sensitive_to:BGB-58067; sensitive_to:BMS-986504; sensitive_to:Balstilimab; sensitive_to:Budigalimab; sensitive_to:Camrelizumab; sensitive_to:Cemiplimab; sensitive_to:Cetrelimab; sensitive_to:Dostarlimab; sensitive_to:EPZ015666; sensitive_to:Ezabenlimab; sensitive_to:Genolimzumab; sensitive_to:Lipustobart; sensitive_to:MEDI0680; sensitive_to:Navlimetostat; sensitive_to:Nivolumab; sensitive_to:Nofazinlimab; sensitive_to:Opucolimab; sensitive_to:PEP08; sensitive_to:PRMT5_inhibitor; sensitive_to:PRMT5_inhibitor + anti-PD-1_monoclonal_antibody; sensitive_to:PRMT5_inhibitor,MTA-co-operative; sensitive_to:PRMT5_inhibitor,MTA-co-operative + anti-PD-1_monoclonal_antibody; sensitive_to:PRT811; sensitive_to:Pembrolizumab; sensitive_to:Penpulimab; sensitive_to:Pimivalimab; sensitive_to:Prolgolimab; sensitive_to:Ralometostat; sensitive_to:Retifanlimab; sensitive_to:Rulonilimab; sensitive_to:Sasanlimab; sensitive_to:Serplulimab; sensitive_to:Sintilimab; sensitive_to:Spartalizumab; sensitive_to:Sym021; sensitive_to:Tislelizumab; sensitive_to:Toripalimab; sensitive_to:Vopimetostat; sensitive_to:YBL006; sensitive_to:Zeluvalimab; sensitive_to:Zimberelimab; sensitive_to:anti-PD-1_monoclonal_antibody (catype:Lymphoma OR catype:Non-Hodgkin's lymphoma OR catype:Peripheral T-cell lymphoma); NOT therapy_recommendation:AZD3470 + Pembrolizumab:U; NOT therapy_recommendation:AZD3470:U; NOT therapy_recommendation:Pembrolizumab:U; preferential_trial_id:NCT06137144 recruitmentstates:NSW,QLD,SA,VIC,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:SA; recruitmentstate:VIC; recruitmentstate:WA facility:2298 - Waratah - Calvary Mater Newcastle Medical Oncology; facility:3065 - Fitzroy - St Vincent's Hospital Melbourne; facility:4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre; facility:4575 - Birtinya - Sunshine Coast University Hospital; facility:5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre; facility:6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre NCT06161974 catype:Astrocytoma; catype:Cancer; catype:Central nervous system cancer; catype:Diffuse intrinsic pontine glioma; catype:Glioma; catype:H3K27M-mutant glioma; catype:High-grade glioma; catype:Low-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Oligodendroglioma; catype:Solid tumour; catype_specific:Astrocytoma; catype_specific:Cancer; catype_specific:Central nervous system cancer; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:Glioma; catype_specific:H3K27M-mutant glioma; catype_specific:High-grade glioma; catype_specific:Oligodendroglioma therapy:IDH1_R132_inhibitor; therapy:IDH1_inhibitor; therapy:IDH1_mutant_selective_inhibitor; therapy:Olutasidenib; therapy:Temozolomide; therapy:alkylating_agent; therapy:cancer_therapy; therapy:cancer_therapy,IDH1-targeting; therapy:cancer_therapy,IDH1_R132-targeting; therapy:cytotoxic_chemotherapy; focused_drug:Olutasidenib; focused_drug:Temozolomide; focused_therapy:IDH1_R132_inhibitor; focused_therapy:IDH1_inhibitor; focused_therapy:IDH1_mutant_selective_inhibitor; focused_therapy:Olutasidenib; focused_therapy:Temozolomide; focused_therapy:alkylating_agent; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,IDH1-targeting; focused_therapy:cancer_therapy,IDH1_R132-targeting; focused_therapy:cytotoxic_chemotherapy; focused_therapy_class:IDH1_R132_inhibitor; focused_therapy_class:alkylating_agent phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Amsacrine; sensitive_to:BAY1436032; sensitive_to:Bendamustine; sensitive_to:Busulfan; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Crelosidenib; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dianhydrogalactitol; sensitive_to:Fotemustine; sensitive_to:GSK321; sensitive_to:IDH1_R132_inhibitor; sensitive_to:IDH1_R132_inhibitor + alkylating_agent; sensitive_to:IDH305; sensitive_to:Ifosfamide; sensitive_to:Ivosidenib; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Olutasidenib; sensitive_to:Olutasidenib + Temozolomide; sensitive_to:Procarbazine; sensitive_to:Safusidenib; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Vorasidenib; sensitive_to:alkylating_agent (catype:High-grade glioma OR catype:Astrocytoma OR catype:Diffuse intrinsic pontine glioma OR catype:Glioma OR catype:Central nervous system cancer OR catype:H3K27M-mutant glioma OR catype:Cancer OR catype:Oligodendroglioma); NOT therapy_recommendation:Olutasidenib + Temozolomide:U; NOT therapy_recommendation:Olutasidenib:U; NOT therapy_recommendation:Temozolomide:U; preferential_trial_id:NCT06161974 recruitmentstates:NSW,QLD,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital NCT06208657 catype:Cancer; catype:Central nervous system cancer; catype:Neurological cancer; catype:Solid tumour; catype_specific:Cancer; catype_specific:Central nervous system cancer; catype_specific:Solid tumour therapy:Irinotecan; therapy:Nivolumab; therapy:PI3K_alpha_inhibitor; therapy:PI3K_delta_inhibitor; therapy:PI3K_inhibitor; therapy:Paxalisib; therapy:Relatlimab; therapy:Temozolomide; therapy:alkylating_agent; therapy:anti-LAG3_monoclonal_antibody; therapy:anti-PD-1_monoclonal_antibody; therapy:cancer_therapy; therapy:cancer_therapy,LAG3-targeting; therapy:cancer_therapy,PD-1-targeting; therapy:cancer_therapy,PD-1/PD-L1-targeting; therapy:cancer_therapy,PI3K-targeting; therapy:cancer_therapy,PI3K_delta-targeting; therapy:cancer_therapy,PI3Kalpha-targeting; therapy:cancer_therapy,mTOR-targeting; therapy:cancer_therapy,mTORC1-targeting; therapy:cancer_therapy,mTORC2-targeting; therapy:cytotoxic_chemotherapy; therapy:dual_PI3K/mTOR_inhibitor; therapy:immune_checkpoint_blockade; therapy:immune_checkpoint_blockade,LAG3-targeting; therapy:immune_checkpoint_blockade,PD-1-targeting; therapy:immuno-oncology_therapy,LAG3-targeting; therapy:immuno-oncology_therapy,PD-1-targeting; therapy:mTORC1/mTORC2_inhibitor; therapy:mTORC1_inhibitor; therapy:mTORC2_inhibitor; therapy:mTOR_inhibitor; therapy:topoisomerase_inhibitor; ; ; phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AI-025; sensitive_to:APL-501; sensitive_to:Alcestobart; sensitive_to:Amsacrine; sensitive_to:BAT-1306; sensitive_to:Balstilimab; sensitive_to:Bendamustine; sensitive_to:Budigalimab; sensitive_to:Busulfan; sensitive_to:Camrelizumab; sensitive_to:Carmustine; sensitive_to:Cemiplimab; sensitive_to:Cetrelimab; sensitive_to:Chlorambucil; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dianhydrogalactitol; sensitive_to:Dostarlimab; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:Ezabenlimab; sensitive_to:FF-10850; sensitive_to:Favezelimab; sensitive_to:Fianlimab; sensitive_to:Fotemustine; sensitive_to:Genolimzumab; sensitive_to:Ieramilimab; sensitive_to:Ifosfamide; sensitive_to:Irinotecan; sensitive_to:Irinotecan + Paxalisib + Temozolomide; sensitive_to:Liposomal Irinotecan; sensitive_to:Lipustobart; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:MEDI0680; sensitive_to:Melphalan; sensitive_to:Miptenalimab; sensitive_to:Negalstobart; sensitive_to:Nivolumab; sensitive_to:Nofazinlimab; sensitive_to:Opucolimab; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Paxalisib; sensitive_to:Pembrolizumab; sensitive_to:Penpulimab; sensitive_to:Pimivalimab; sensitive_to:Procarbazine; sensitive_to:Prolgolimab; sensitive_to:Relatlimab; sensitive_to:Retifanlimab; sensitive_to:Rulonilimab; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Sasanlimab; sensitive_to:Serplulimab; sensitive_to:Sintilimab; sensitive_to:Spartalizumab; sensitive_to:Streptozotocin; sensitive_to:Sym021; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Tislelizumab; sensitive_to:Topotecan; sensitive_to:Toripalimab; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:YBL006; sensitive_to:Zeluvalimab; sensitive_to:Zimberelimab; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; sensitive_to:anti-LAG3_monoclonal_antibody; sensitive_to:anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; sensitive_to:anti-PD-1_monoclonal_antibody; sensitive_to:dual_PI3K/mTOR_inhibitor; sensitive_to:topoisomerase_inhibitor (catype:Cancer OR catype:Solid tumour OR catype:Central nervous system cancer); NOT therapy_recommendation:Irinotecan + Paxalisib + Temozolomide:U; NOT therapy_recommendation:Irinotecan:U; NOT therapy_recommendation:Paxalisib:U; NOT therapy_recommendation:Temozolomide:U; NOT therapy_recommendation:anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody:U; preferential_trial_id:NCT06208657; trial_type:paediatric recruitmentstates:NSW,QLD,SA,TAS,VIC,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:SA; recruitmentstate:TAS; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:2145 - Westmead - The Children's Hospital at Westmead; facility:2305 - New Lambton Heights - John Hunter Children's Hospital; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:3168 - Clayton - Monash Children's Hospital; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; facility:6009 - Perth - Perth Children's Hospital; facility:7000 - Hobart - Royal Hobart Hospital NCT06302426 catype:Cancer; catype:Solid tumour; catype_specific:Solid tumour therapy:Atezolizumab; therapy:Avelumab; therapy:Cemiplimab; therapy:Durvalumab; therapy:INI-4001; therapy:Nivolumab; therapy:Pembrolizumab; therapy:TLR7/TLR8_agonist; therapy:anti-PD-1_monoclonal_antibody; therapy:anti-PD-L1_monoclonal_antibody; therapy:cancer_therapy; therapy:cancer_therapy,PD-1-targeting; therapy:cancer_therapy,PD-1/PD-L1-targeting; therapy:cancer_therapy,PD-L1-targeting; therapy:cancer_therapy,TLR7/TLR8-targeting; therapy:immune_checkpoint_blockade; therapy:immune_checkpoint_blockade,PD-1-targeting; therapy:immune_checkpoint_blockade,PD-L1-targeting; therapy:immuno-oncology_therapy,PD-1-targeting; therapy:immuno-oncology_therapy,PD-L1-targeting; focused_drug:INI-4001; focused_therapy:INI-4001; focused_therapy:TLR7/TLR8_agonist; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,TLR7/TLR8-targeting; focused_therapy_class:TLR7/TLR8_agonist phase:Phase 1 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AI-025; sensitive_to:APL-501; sensitive_to:Adebrelimab; sensitive_to:Atezolizumab; sensitive_to:Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab; sensitive_to:Avelumab; sensitive_to:BAT-1306; sensitive_to:BMS 936559; sensitive_to:Balstilimab; sensitive_to:Benmelstobart; sensitive_to:Budigalimab; sensitive_to:Camrelizumab; sensitive_to:Cemiplimab; sensitive_to:Cetrelimab; sensitive_to:Cosibelimab; sensitive_to:Dostarlimab; sensitive_to:Durvalumab; sensitive_to:Envafolimab; sensitive_to:Evixapodlin; sensitive_to:Ezabenlimab; sensitive_to:FAZ-053; sensitive_to:GR-1405; sensitive_to:Garivulimab; sensitive_to:Genolimzumab; sensitive_to:INI-4001; sensitive_to:Lipustobart; sensitive_to:Lodapolimab; sensitive_to:MEDI0680; sensitive_to:Manelimab; sensitive_to:Nivolumab; sensitive_to:Nofazinlimab; sensitive_to:Opucolimab; sensitive_to:Pacmilimab; sensitive_to:Pembrolizumab; sensitive_to:Penpulimab; sensitive_to:Pimivalimab; sensitive_to:Prolgolimab; sensitive_to:Resiquimod; sensitive_to:Retifanlimab; sensitive_to:Rulonilimab; sensitive_to:Sasanlimab; sensitive_to:Serplulimab; sensitive_to:Sintilimab; sensitive_to:Socazolimab; sensitive_to:Spartalizumab; sensitive_to:Sugemalimab; sensitive_to:Sym021; sensitive_to:TLR7/TLR8_agonist; sensitive_to:TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; sensitive_to:Tagitanlimab; sensitive_to:Tislelizumab; sensitive_to:Toripalimab; sensitive_to:TransCon TLR7/8 agonist; sensitive_to:YBL006; sensitive_to:Zeluvalimab; sensitive_to:Zimberelimab; sensitive_to:anti-PD-1_monoclonal_antibody; sensitive_to:anti-PD-L1_monoclonal_antibody NOT therapy_recommendation:Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab:U; NOT therapy_recommendation:Atezolizumab:U; NOT therapy_recommendation:Avelumab:U; NOT therapy_recommendation:Cemiplimab:U; NOT therapy_recommendation:Durvalumab:U; NOT therapy_recommendation:INI-4001:U; NOT therapy_recommendation:Nivolumab:U; NOT therapy_recommendation:Pembrolizumab:U; preferential_trial_id:NCT06302426 recruitmentstates:NSW,SA,VIC; recruitmentstate:NSW; recruitmentstate:SA; recruitmentstate:VIC facility:2640 - Albury - Border Medical Oncology Research Unit; facility:3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre; facility:5042 - Bedford Park - Southern Oncology Clinical Research Unit NCT06304818 catype:Cancer; catype:Solid tumour; catype_specific:Solid tumour therapy:SCTB14; therapy:bispecific_PD-1/VEGF_antibody; therapy:cancer_therapy; therapy:cancer_therapy,PD-1-targeting; therapy:cancer_therapy,PD-1/PD-L1-targeting; therapy:cancer_therapy,VEGF-targeting; therapy:immune_checkpoint_blockade; therapy:immune_checkpoint_blockade,PD-1-targeting; therapy:immuno-oncology_therapy,PD-1-targeting; therapy:immuno-oncology_therapy,VEGF-targeting; focused_drug:SCTB14; focused_therapy:SCTB14; focused_therapy:bispecific_PD-1/VEGF_antibody; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,PD-1-targeting; focused_therapy:cancer_therapy,PD-1/PD-L1-targeting; focused_therapy:cancer_therapy,VEGF-targeting; focused_therapy:immune_checkpoint_blockade; focused_therapy:immune_checkpoint_blockade,PD-1-targeting; focused_therapy:immuno-oncology_therapy,PD-1-targeting; focused_therapy:immuno-oncology_therapy,VEGF-targeting; focused_therapy_class:bispecific_PD-1/VEGF_antibody phase:Phase 1; phase:Phase 2 recruitmentstatus:NOT_YET_RECRUITING; recruitmentstatus_active:true sensitive_to:CR-001; sensitive_to:Ivonescimab; sensitive_to:JS-207; sensitive_to:LM-299; sensitive_to:PF-08634404; sensitive_to:SCTB14; sensitive_to:bispecific_PD-1/VEGF_antibody NOT therapy_recommendation:SCTB14:U; preferential_trial_id:NCT06304818; recruitment_status:NOT_YET_RECRUITING recruitmentstates: NCT06333899 catype:Anaplastic astrocytoma; catype:Cancer; catype:Central nervous system cancer; catype:Diffuse intrinsic pontine glioma; catype:Diffuse midline glioma; catype:Glioblastoma; catype:Glioma; catype:H3K27M-mutant glioma; catype:High-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Anaplastic astrocytoma; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:Diffuse midline glioma; catype_specific:Glioblastoma; catype_specific:Glioma; catype_specific:High-grade glioma therapy:ALK_inhibitor; therapy:ALK_inhibitor,third_generation; therapy:Carboplatin; therapy:Cisplatin; therapy:Cyclophosphamide; therapy:DPD_inhibitor; therapy:Lorlatinib; therapy:Methotrexate; therapy:ROS1_inhibitor; therapy:Radiotherapy; therapy:Tegafur-gimeracil-oteracil potassium; therapy:Vincristine; therapy:alkylating_agent; therapy:antifolate; therapy:antimetabolite; therapy:cancer_therapy; therapy:cancer_therapy,ALK-targeting; therapy:cancer_therapy,DPD-targeting; therapy:cancer_therapy,ROS1-targeting; therapy:cancer_therapy,orotate_phosphoribosyltransferase-targeting; therapy:cytotoxic_chemotherapy; therapy:orotate_phosphoribosyltransferase_inhibitor; therapy:platinum-based_antineoplastic_agent; therapy:vinca_alkaloid; focused_drug:Lorlatinib; focused_therapy:ALK_inhibitor; focused_therapy:ALK_inhibitor,third_generation; focused_therapy:Lorlatinib; focused_therapy:ROS1_inhibitor; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,ALK-targeting; focused_therapy:cancer_therapy,ROS1-targeting; focused_therapy_class:ALK_inhibitor,third_generation; focused_therapy_class:ROS1_inhibitor phase:Phase 1 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:ALK_inhibitor,third_generation; sensitive_to:ALK_inhibitor,third_generation + alkylating_agent + antifolate + platinum-based_antineoplastic_agent + vinca_alkaloid; sensitive_to:ALK_inhibitor,third_generation + alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + vinca_alkaloid; sensitive_to:ALK_inhibitor,third_generation + alkylating_agent + platinum-based_antineoplastic_agent + vinca_alkaloid; sensitive_to:ALK_inhibitor,third_generation + radiotherapy; sensitive_to:APG-2449; sensitive_to:AZD3463; sensitive_to:Amsacrine; sensitive_to:Azacitidine; sensitive_to:Bendamustine; sensitive_to:Bisantrene; sensitive_to:Brigatinib; sensitive_to:Busulfan; sensitive_to:Bzacitidine; sensitive_to:Cabozantinib; sensitive_to:Capecitabine; sensitive_to:Carboplatin; sensitive_to:Carboplatin + Cyclophosphamide + Lorlatinib + Methotrexate + Vincristine; sensitive_to:Carmustine; sensitive_to:Ceritinib; sensitive_to:Chlorambucil; sensitive_to:Cisplatin; sensitive_to:Cisplatin + Cyclophosphamide + Lorlatinib + Vincristine; sensitive_to:Cladribine; sensitive_to:Crizotinib; sensitive_to:Cyclophosphamide; sensitive_to:Cytarabine; sensitive_to:DPD_inhibitor; sensitive_to:Dacarbazine; sensitive_to:Deflexifol; sensitive_to:Dianhydrogalactitol; sensitive_to:Ensartinib; sensitive_to:Entrectinib; sensitive_to:Fludarabine; sensitive_to:Fluorouracil; sensitive_to:Foretinib; sensitive_to:Fotemustine; sensitive_to:Gemcitabine; sensitive_to:Hydroxyurea; sensitive_to:IGF1R_inhibitor; sensitive_to:Ifosfamide; sensitive_to:Intensity Modulated Radiotherapy; sensitive_to:Lometrexol; sensitive_to:Lomustine; sensitive_to:Lorlatinib; sensitive_to:Lorlatinib + Radiotherapy; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Methotrexate; sensitive_to:OncoSil; sensitive_to:Oxaliplatin; sensitive_to:Pemetrexed; sensitive_to:Procarbazine; sensitive_to:ROS1_inhibitor; sensitive_to:ROS1_inhibitor + alkylating_agent + antifolate + platinum-based_antineoplastic_agent + vinca_alkaloid; sensitive_to:ROS1_inhibitor + alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + vinca_alkaloid; sensitive_to:ROS1_inhibitor + alkylating_agent + platinum-based_antineoplastic_agent + vinca_alkaloid; sensitive_to:ROS1_inhibitor + radiotherapy; sensitive_to:Radiotherapy; sensitive_to:Raltitrexed; sensitive_to:Repotrectinib; sensitive_to:Streptozotocin; sensitive_to:Taletrectinib; sensitive_to:Tegafur; sensitive_to:Tegafur-gimeracil-oteracil potassium; sensitive_to:Temozolomide; sensitive_to:Thioguanine; sensitive_to:Thiotepa; sensitive_to:Thoracic Radiation Therapy; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Trifluridine/Tipiracil; sensitive_to:Vinblastine; sensitive_to:Vincristine; sensitive_to:Vinflunine; sensitive_to:Vinorelbine; sensitive_to:Zidesamtinib; sensitive_to:alkylating_agent; sensitive_to:antimetabolite; sensitive_to:orotate_phosphoribosyltransferase_inhibitor; sensitive_to:platinum-based_antineoplastic_agent; sensitive_to:radiotherapy; sensitive_to:vinca_alkaloid (catype:High-grade glioma OR catype:Diffuse intrinsic pontine glioma OR catype:Anaplastic astrocytoma OR catype:Glioma OR catype:Glioblastoma OR catype:Diffuse midline glioma); NOT therapy_recommendation:Carboplatin + Cyclophosphamide + Lorlatinib + Methotrexate + Vincristine:U; NOT therapy_recommendation:Carboplatin:U; NOT therapy_recommendation:Cisplatin + Cyclophosphamide + Lorlatinib + Vincristine:U; NOT therapy_recommendation:Cisplatin:U; NOT therapy_recommendation:Cyclophosphamide:U; NOT therapy_recommendation:Lorlatinib + Radiotherapy:U; NOT therapy_recommendation:Lorlatinib:U; NOT therapy_recommendation:Methotrexate:U; NOT therapy_recommendation:Radiotherapy:U; NOT therapy_recommendation:Tegafur-gimeracil-oteracil potassium:U; NOT therapy_recommendation:Vincristine:U; preferential_trial_id:NCT06333899 recruitmentstates:NSW,NZ,QLD,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital NCT06381570 catype:Cancer; catype:Central nervous system cancer; catype:Glioma; catype:Low-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Low-grade glioma therapy:ARAF_inhibitor; therapy:BRAF_inhibitor; therapy:CRAF_inhibitor; therapy:RAF_inhibitor; therapy:RAF_inhibitor,type_2; therapy:Tovorafenib; therapy:Vinblastine; therapy:cancer_therapy; therapy:cancer_therapy,BRAF-targeting; therapy:cancer_therapy,CRAF-targeting; therapy:cancer_therapy,RAF-targeting; therapy:cancer_therapy,pan-RAF-targeting; therapy:cytotoxic_chemotherapy; therapy:pan-RAF_inhibitor; therapy:vinca_alkaloid; focused_drug:Tovorafenib; focused_drug:Vinblastine; focused_therapy:ARAF_inhibitor; focused_therapy:BRAF_inhibitor; focused_therapy:CRAF_inhibitor; focused_therapy:RAF_inhibitor; focused_therapy:RAF_inhibitor,type_2; focused_therapy:Tovorafenib; focused_therapy:Vinblastine; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,BRAF-targeting; focused_therapy:cancer_therapy,CRAF-targeting; focused_therapy:cancer_therapy,RAF-targeting; focused_therapy:cancer_therapy,pan-RAF-targeting; focused_therapy:cytotoxic_chemotherapy; focused_therapy:pan-RAF_inhibitor; focused_therapy:vinca_alkaloid; focused_therapy_class:RAF_inhibitor,type_2; focused_therapy_class:vinca_alkaloid phase:Phase 0 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:BGB659; sensitive_to:LY3009120; sensitive_to:RAF_inhibitor,type_2; sensitive_to:TAK-632; sensitive_to:Tovorafenib; sensitive_to:Vinblastine; sensitive_to:Vincristine; sensitive_to:Vinflunine; sensitive_to:Vinorelbine; sensitive_to:vinca_alkaloid NOT therapy_recommendation:Tovorafenib:U; NOT therapy_recommendation:Vinblastine:U; preferential_trial_id:NCT06381570 recruitmentstates: NCT06395103 catype:Acute lymphoblastic leukaemia; catype:B-cell acute lymphoblastic leukaemia/lymphoma; catype:B-cell lymphoma; catype:B-cell malignancy; catype:Bone cancer; catype:Burkitt lymphoma; catype:Cancer; catype:Diffuse large B-cell lymphoma; catype:Ewing family of tumours; catype:Ewing sarcoma; catype:Haematological malignancy; catype:High-grade B-cell lymphoma; catype:Leukaemia; catype:Lymphoid leukaemia; catype:Lymphoma; catype:Mature B-cell malignancy; catype:Neuroblastic tumour; catype:Neuroblastoma; catype:Neurological cancer; catype:Non-Hodgkin's lymphoma; catype:Peripheral nervous system tumour; catype:Primitive neuroectodermal tumour; catype:Sarcoma; catype:Solid tumour; catype_specific:B-cell acute lymphoblastic leukaemia/lymphoma; catype_specific:Burkitt lymphoma; catype_specific:Diffuse large B-cell lymphoma; catype_specific:Ewing sarcoma; catype_specific:Neuroblastoma therapy:Zilovertamab vedotin; therapy:anti-ROR1_antibody-drug_conjugate; therapy:cancer_therapy; therapy:cancer_therapy,ROR1-targeting; therapy:immuno-oncology_therapy,ROR1-targeting; focused_drug:Zilovertamab vedotin; focused_therapy:Zilovertamab vedotin; focused_therapy:anti-ROR1_antibody-drug_conjugate; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,ROR1-targeting; focused_therapy:immuno-oncology_therapy,ROR1-targeting; focused_therapy_class:anti-ROR1_antibody-drug_conjugate phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:CS5001; sensitive_to:Zilovertamab vedotin; sensitive_to:anti-ROR1_antibody-drug_conjugate (catype:B-cell acute lymphoblastic leukaemia/lymphoma OR catype:Diffuse large B-cell lymphoma OR catype:Burkitt lymphoma OR catype:Neuroblastoma OR catype:Ewing sarcoma); NOT therapy_recommendation:Zilovertamab vedotin:U; preferential_trial_id:NCT06395103 recruitmentstates:NSW,QLD,VIC; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:VIC facility:2031 - Randwick - Sydney Children's Hospital; facility:3052 - Parkville - Royal Children's Hospital Melbourne; facility:4101 - South Brisbane - Queensland Children's Hospital NCT06401330 catype:Cancer; catype:Sarcoma; catype:Solid tumour; catype:Wilms tumour; catype_specific:Wilms tumour therapy:Carboplatin; therapy:Cyclophosphamide; therapy:Dactinomycin; therapy:Doxorubicin; therapy:Etoposide; therapy:Irinotecan; therapy:Vincristine; therapy:alkylating_agent; therapy:anthracycline; therapy:antineoplastic_antibiotic; therapy:cancer_therapy; therapy:cytotoxic_chemotherapy; therapy:platinum-based_antineoplastic_agent; therapy:topoisomerase_inhibitor; therapy:vinca_alkaloid; ; ; phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Aldoxorubicin; sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Bleomycin; sensitive_to:Busulfan; sensitive_to:Carboplatin; sensitive_to:Carboplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; sensitive_to:Carboplatin + Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Vincristine; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cisplatin; sensitive_to:Cyclophosphamide; sensitive_to:Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide; sensitive_to:Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; sensitive_to:Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine; sensitive_to:Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Vincristine; sensitive_to:Cyclophosphamide + Doxorubicin + Etoposide + Vincristine; sensitive_to:Dacarbazine; sensitive_to:Dactinomycin; sensitive_to:Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; sensitive_to:Dactinomycin + Doxorubicin + Vincristine; sensitive_to:Dactinomycin + Irinotecan + Vincristine; sensitive_to:Dactinomycin + Vincristine; sensitive_to:Dianhydrogalactitol; sensitive_to:Doxorubicin; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10850; sensitive_to:Fotemustine; sensitive_to:IMX-110; sensitive_to:Ifosfamide; sensitive_to:Irinotecan; sensitive_to:Liposomal Irinotecan; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Mitomycin; sensitive_to:Mitoxantrone; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Oxaliplatin; sensitive_to:Procarbazine; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Salinomycin; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Topotecan; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:Vinblastine; sensitive_to:Vincristine; sensitive_to:Vinflunine; sensitive_to:Vinorelbine; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + anthracycline + antineoplastic_antibiotic + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; sensitive_to:alkylating_agent + anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor; sensitive_to:alkylating_agent + anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; sensitive_to:alkylating_agent + anthracycline + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; sensitive_to:alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; sensitive_to:anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; sensitive_to:anthracycline + antineoplastic_antibiotic + vinca_alkaloid; sensitive_to:antineoplastic_antibiotic; sensitive_to:antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; sensitive_to:antineoplastic_antibiotic + vinca_alkaloid; sensitive_to:doxorubicin; sensitive_to:platinum-based_antineoplastic_agent; sensitive_to:topoisomerase_inhibitor; sensitive_to:vinca_alkaloid NOT therapy_recommendation:Carboplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine:U; NOT therapy_recommendation:Carboplatin + Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Vincristine:U; NOT therapy_recommendation:Carboplatin:U; NOT therapy_recommendation:Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine:U; NOT therapy_recommendation:Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine:U; NOT therapy_recommendation:Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide:U; NOT therapy_recommendation:Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Vincristine:U; NOT therapy_recommendation:Cyclophosphamide + Doxorubicin + Etoposide + Vincristine:U; NOT therapy_recommendation:Cyclophosphamide:U; NOT therapy_recommendation:Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine:U; NOT therapy_recommendation:Dactinomycin + Doxorubicin + Vincristine:U; NOT therapy_recommendation:Dactinomycin + Irinotecan + Vincristine:U; NOT therapy_recommendation:Dactinomycin + Vincristine:U; NOT therapy_recommendation:Dactinomycin:U; NOT therapy_recommendation:Doxorubicin:U; NOT therapy_recommendation:Etoposide:U; NOT therapy_recommendation:Irinotecan:U; NOT therapy_recommendation:Vincristine:U; preferential_trial_id:NCT06401330 recruitmentstates:QLD; recruitmentstate:QLD facility:4101 - South Brisbane - Queensland Children's Hospital NCT06414148 catype:B-cell lymphoma; catype:B-cell malignancy; catype:Cancer; catype:Diffuse large B-cell lymphoma; catype:Haematological malignancy; catype:High-grade B-cell lymphoma; catype:Lymphoma; catype:Mature B-cell malignancy; catype:Non-Hodgkin's lymphoma; catype_specific:Diffuse large B-cell lymphoma therapy:Epcoritamab; therapy:Lenalidomide; therapy:Rituximab; therapy:anti-CD20_monoclonal_antibody; therapy:bispecific_T-cell_engager,CD20-targeting; therapy:cancer_therapy; therapy:cancer_therapy,CD20-targeting; therapy:cancer_therapy,cereblon-targeting; therapy:cereblon_modulator; therapy:immuno-oncology_therapy,CD20-targeting; therapy:immunomodulatory_imide_drug; therapy:therapeutic_modality,bispecific_T-cell_engager; therapy:therapeutic_modality,bispecific_antibody; focused_drug:Epcoritamab; focused_drug:Lenalidomide; focused_drug:Rituximab; focused_therapy:Epcoritamab; focused_therapy:Lenalidomide; focused_therapy:Rituximab; focused_therapy:anti-CD20_monoclonal_antibody; focused_therapy:bispecific_T-cell_engager,CD20-targeting; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CD20-targeting; focused_therapy:cancer_therapy,cereblon-targeting; focused_therapy:cereblon_modulator; focused_therapy:immuno-oncology_therapy,CD20-targeting; focused_therapy:immunomodulatory_imide_drug; focused_therapy:therapeutic_modality,bispecific_T-cell_engager; focused_therapy:therapeutic_modality,bispecific_antibody; focused_therapy_class:anti-CD20_monoclonal_antibody; focused_therapy_class:bispecific_T-cell_engager,CD20-targeting; focused_therapy_class:immunomodulatory_imide_drug phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AZD5492; sensitive_to:Epcoritamab; sensitive_to:Epcoritamab + Lenalidomide + Rituximab; sensitive_to:GB261; sensitive_to:Glofitamab; sensitive_to:Imvotamab; sensitive_to:Lenalidomide; sensitive_to:Mosunetuzumab; sensitive_to:Obinutuzumab; sensitive_to:Odronextamab; sensitive_to:Ofatumumab; sensitive_to:Pomalidomide; sensitive_to:Rituximab; sensitive_to:Thalidomide; sensitive_to:Ublituximab; sensitive_to:anti-CD20_monoclonal_antibody; sensitive_to:anti-CD20_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting + immunomodulatory_imide_drug; sensitive_to:bispecific_T-cell_engager,CD20-targeting; sensitive_to:immunomodulatory_imide_drug NOT therapy_recommendation:Epcoritamab + Lenalidomide + Rituximab:U; NOT therapy_recommendation:Epcoritamab:U; NOT therapy_recommendation:Lenalidomide:U; NOT therapy_recommendation:Rituximab:U; preferential_trial_id:NCT06414148 recruitmentstates:NSW,QLD,VIC,WA; recruitmentstate:NSW; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:2050 - Camperdown - Chris O'Brien Lifehouse; facility:2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital; facility:3000 - Melbourne - Peter MacCallum Cancer Centre; facility:3004 - Melbourne, Southbank - Alfred Health; facility:4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre; facility:6150 - Murdoch - Fiona Stanley Hospital NCT06514794 catype:Acute lymphoblastic leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoid leukaemia; catype:Lymphoma; catype:T-cell acute lymphoblastic leukaemia/lymphoma; catype_specific:Lymphoma; catype_specific:T-cell acute lymphoblastic leukaemia/lymphoma therapy:CAR-T-cell_therapy; therapy:CAR-T-cell_therapy,CD7-targeting; therapy:WU-CART-007; therapy:allogeneic_CAR-T-cell_therapy; therapy:allogeneic_CAR-T-cell_therapy,CD7-targeting; therapy:cancer_therapy; therapy:cancer_therapy,CD7-targeting; therapy:cell_therapy; focused_drug:WU-CART-007; focused_therapy:CAR-T-cell_therapy; focused_therapy:CAR-T-cell_therapy,CD7-targeting; focused_therapy:WU-CART-007; focused_therapy:allogeneic_CAR-T-cell_therapy; focused_therapy:allogeneic_CAR-T-cell_therapy,CD7-targeting; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CD7-targeting; focused_therapy:cell_therapy; focused_therapy_class:allogeneic_CAR-T-cell_therapy,CD7-targeting phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:WU-CART-007; sensitive_to:allogeneic_CAR-T-cell_therapy,CD7-targeting (catype:T-cell acute lymphoblastic leukaemia/lymphoma OR catype:Lymphoma); NOT therapy_recommendation:WU-CART-007:U; preferential_trial_id:NCT06514794 recruitmentstates:VIC; recruitmentstate:VIC facility:3000 - Melbourne - Peter MacCallum Cancer Centre; facility:3052 - Parkville - Royal Children's Hospital Melbourne NCT06838676 catype:Cancer; catype:Central nervous system cancer; catype:Diffuse intrinsic pontine glioma; catype:Glioma; catype:H3K27M-mutant glioma; catype:High-grade glioma; catype:Malignant glioma; catype:Neurological cancer; catype:Solid tumour; catype_specific:Diffuse intrinsic pontine glioma; catype_specific:High-grade glioma therapy:DMAMCL; therapy:NFKB_inhibitor; therapy:cancer_therapy; therapy:cancer_therapy,NFKB-targeting; focused_drug:DMAMCL; focused_therapy:DMAMCL; focused_therapy:NFKB_inhibitor; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,NFKB-targeting; focused_therapy_class:NFKB_inhibitor phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:DMAMCL; sensitive_to:NFKB_inhibitor (catype:Diffuse intrinsic pontine glioma OR catype:High-grade glioma); NOT therapy_recommendation:DMAMCL:U; preferential_trial_id:NCT06838676 recruitmentstates:NSW,NZ,QLD,VIC,WA; recruitmentstate:NSW; recruitmentstate:NZ; recruitmentstate:QLD; recruitmentstate:VIC; recruitmentstate:WA facility:2031 - Randwick - Sydney Children's Hospital; facility:3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; facility:4101 - South Brisbane - Queensland Children's Hospital; facility:6009 - Perth - Perth Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital NCT06876649 catype:B-cell malignancy; catype:Cancer; catype:Chronic lymphocytic leukaemia; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoid leukaemia; catype:Lymphoma; catype:Mature B-cell malignancy; catype:Non-Hodgkin's lymphoma; catype_specific:Chronic lymphocytic leukaemia; catype_specific:Non-Hodgkin's lymphoma therapy:BTK_inhibitor; therapy:Pirtobrutinib; therapy:cancer_therapy; therapy:cancer_therapy,BTK-targeting; focused_drug:Pirtobrutinib; focused_therapy:BTK_inhibitor; focused_therapy:Pirtobrutinib; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,BTK-targeting; focused_therapy_class:BTK_inhibitor phase:Phase 4 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:ABBV-992; sensitive_to:Acalabrutinib; sensitive_to:BTK_inhibitor; sensitive_to:HMPL-760; sensitive_to:Ibrutinib; sensitive_to:Nemtabrutinib; sensitive_to:Pirtobrutinib; sensitive_to:TL-895; sensitive_to:Zanubrutinib; sensitive_to:Zelebrudomide (catype:Chronic lymphocytic leukaemia OR catype:Non-Hodgkin's lymphoma); NOT therapy_recommendation:Pirtobrutinib:U; preferential_trial_id:NCT06876649; prior_therapy:Pirtobrutinib recruitmentstates:SA,VIC,WA; recruitmentstate:SA; recruitmentstate:VIC; recruitmentstate:WA facility:3000 - Melbourne - Peter MacCallum Cancer Centre; facility:5042 - Bedford Park - Flinders Medical Centre; facility:6009 - Nedlands - Linear Clinical Research NCT06941272 catype:Cancer; catype_specific:Cancer therapy:Patritumab Deruxtecan; therapy:anti-ERBB3_antibody-drug_conjugate; therapy:cancer_therapy; therapy:cancer_therapy,ERBB3-targeting; therapy:immuno-oncology_therapy,ERBB3-targeting; focused_drug:Patritumab Deruxtecan; focused_therapy:Patritumab Deruxtecan; focused_therapy:anti-ERBB3_antibody-drug_conjugate; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,ERBB3-targeting; focused_therapy:immuno-oncology_therapy,ERBB3-targeting; focused_therapy_class:anti-ERBB3_antibody-drug_conjugate phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AK138D1; sensitive_to:AMT-562; sensitive_to:Beruzatatug pelitecan; sensitive_to:DB-1310; sensitive_to:ENV-501; sensitive_to:Patritumab Deruxtecan; sensitive_to:anti-ERBB3_antibody-drug_conjugate NOT therapy_recommendation:Patritumab Deruxtecan:U; preferential_trial_id:NCT06941272 recruitmentstates:NSW,QLD; recruitmentstate:NSW; recruitmentstate:QLD facility:2031 - Randwick - Sydney Children's Hospital; facility:4101 - South Brisbane - Queensland Children's Hospital NCT07060807 catype:Breast cancer; catype:Cancer; catype:Solid tumour; catype_specific:Breast cancer therapy:Capecitabine; therapy:Nab-paclitaxel; therapy:Paclitaxel; therapy:Patritumab Deruxtecan; therapy:Pegylated liposomal doxorubicin; therapy:Trastuzumab Deruxtecan; therapy:anthracycline; therapy:anti-ERBB2_antibody-drug_conjugate; therapy:anti-ERBB3_antibody-drug_conjugate; therapy:antimetabolite; therapy:cancer_therapy; therapy:cancer_therapy,ERBB2-targeting; therapy:cancer_therapy,ERBB3-targeting; therapy:cytotoxic_chemotherapy; therapy:fluoropyrimidine; therapy:immuno-oncology_therapy,ERBB2-targeting; therapy:immuno-oncology_therapy,ERBB3-targeting; therapy:taxane; focused_drug:Patritumab Deruxtecan; focused_therapy:Patritumab Deruxtecan; focused_therapy:anti-ERBB3_antibody-drug_conjugate; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,ERBB3-targeting; focused_therapy:immuno-oncology_therapy,ERBB3-targeting; focused_therapy_class:anti-ERBB3_antibody-drug_conjugate phase:Phase 3 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AK138D1; sensitive_to:AMT-562; sensitive_to:Aldoxorubicin; sensitive_to:Amrubicin; sensitive_to:Anbenitamab Repodatecan; sensitive_to:Anvatabart Opadotin; sensitive_to:Berubicin; sensitive_to:Beruzatatug pelitecan; sensitive_to:Bisantrene; sensitive_to:CLIO-8221; sensitive_to:Cabazitaxel; sensitive_to:Capecitabine; sensitive_to:Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Trastuzumab Deruxtecan; sensitive_to:Caxmotabart Entudotin; sensitive_to:DB-1310; sensitive_to:Daunorubicin; sensitive_to:Deflexifol; sensitive_to:Disitamab vedotin; sensitive_to:Docetaxel; sensitive_to:Doxorubicin; sensitive_to:ENV-501; sensitive_to:Epirubicin; sensitive_to:Fluorouracil; sensitive_to:GQ1001; sensitive_to:GQ1007; sensitive_to:IBI354; sensitive_to:IMX-110; sensitive_to:Idarubicin; sensitive_to:MT-5111; sensitive_to:Nab-paclitaxel; sensitive_to:Oral Docetaxel; sensitive_to:Oraxol; sensitive_to:PF-03732010; sensitive_to:Paclitaxel; sensitive_to:Patritumab Deruxtecan; sensitive_to:Pegylated liposomal doxorubicin; sensitive_to:SBT6050; sensitive_to:SHR-4602; sensitive_to:SQ3370; sensitive_to:Tegafur; sensitive_to:Tesetaxel; sensitive_to:Trastuzumab Deruxtecan; sensitive_to:Trastuzumab Emtansine; sensitive_to:Trastuzumab Pamirtecan; sensitive_to:Trastuzumab Rezetecan; sensitive_to:Trastuzumab duocarmazine; sensitive_to:Zanidatamab Zovodotin; sensitive_to:anthracycline; sensitive_to:anthracycline + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine + taxane; sensitive_to:anti-ERBB2_antibody-drug_conjugate; sensitive_to:anti-ERBB3_antibody-drug_conjugate; sensitive_to:fluoropyrimidine; sensitive_to:taxane NOT BRCA:oncogenic_mutation,germline; NOT ERBB2:amplification; NOT ERBB2:overexpression; NOT prior_therapy:cancer_therapy,ERBB3-targeting; NOT prior_therapy:chemotherapy; NOT prior_therapy:topoisomerase_I_inhibitor; NOT therapy_recommendation:Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Trastuzumab Deruxtecan:U; NOT therapy_recommendation:Capecitabine:U; NOT therapy_recommendation:Nab-paclitaxel:U; NOT therapy_recommendation:Paclitaxel:U; NOT therapy_recommendation:Patritumab Deruxtecan:U; NOT therapy_recommendation:Pegylated liposomal doxorubicin:U; NOT therapy_recommendation:Trastuzumab Deruxtecan:U; preferential_trial_id:NCT07060807; prior_therapy:CDK4/6_inhibitor; prior_therapy:endocrine_therapy recruitmentstates:NSW,VIC; recruitmentstate:NSW; recruitmentstate:VIC facility:2050 - Camperdown - Chris O'Brien Lifehouse; facility:2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre; facility:3004 - Melbourne, Southbank - Alfred Health; facility:3168 - Clayton - Monash Medical Centre NCT07109219 catype:Acute lymphoblastic leukaemia; catype:B-cell acute lymphoblastic leukaemia/lymphoma; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Lymphoid leukaemia; catype_specific:B-cell acute lymphoblastic leukaemia/lymphoma therapy:AZD4512; therapy:anti-CD22_antibody-drug_conjugate; therapy:cancer_therapy; therapy:cancer_therapy,CD22-targeting; therapy:immuno-oncology_therapy,CD22-targeting; focused_drug:AZD4512; focused_therapy:AZD4512; focused_therapy:anti-CD22_antibody-drug_conjugate; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,CD22-targeting; focused_therapy:immuno-oncology_therapy,CD22-targeting; focused_therapy_class:anti-CD22_antibody-drug_conjugate phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:AZD4512; sensitive_to:Inotuzumab ozogamicin; sensitive_to:anti-CD22_antibody-drug_conjugate NOT therapy_recommendation:AZD4512:U; preferential_trial_id:NCT07109219 recruitmentstates:VIC; recruitmentstate:VIC facility:3000 - Melbourne - Peter MacCallum Cancer Centre NCT07190300 catype:Cancer; catype:Castrate-sensitive prostate cancer; catype:Male genital cancers; catype:Prostate adenocarcinoma; catype:Prostate cancer; catype:Solid tumour; catype:Urogenital cancer; catype_specific:Castrate-sensitive prostate cancer therapy:AR-targeted_agent,next_generation; therapy:AR-targeted_agent,second_generation; therapy:Abiraterone; therapy:CYP17A1_inhibitor; therapy:Darolutamide; therapy:EZH1/2_inhibitor; therapy:EZH1_inhibitor; therapy:EZH2_inhibitor; therapy:Tulmimetostat; therapy:antiandrogen; therapy:antiandrogen,nonsteroidal; therapy:antiandrogen,nonsteroidal,second_generation; therapy:cancer_therapy; therapy:cancer_therapy,AR-targeting; therapy:cancer_therapy,CYP17A1-targeting; therapy:cancer_therapy,EZH1-targeting; therapy:cancer_therapy,EZH2-targeting; therapy:endocrine_therapy; therapy:endocrine_therapy,androgen_axis-targeting; focused_drug:Abiraterone; focused_drug:Darolutamide; focused_drug:Tulmimetostat; focused_therapy:AR-targeted_agent,next_generation; focused_therapy:AR-targeted_agent,second_generation; focused_therapy:Abiraterone; focused_therapy:CYP17A1_inhibitor; focused_therapy:Darolutamide; focused_therapy:EZH1/2_inhibitor; focused_therapy:EZH1_inhibitor; focused_therapy:EZH2_inhibitor; focused_therapy:Tulmimetostat; focused_therapy:antiandrogen; focused_therapy:antiandrogen,nonsteroidal; focused_therapy:antiandrogen,nonsteroidal,second_generation; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,AR-targeting; focused_therapy:cancer_therapy,CYP17A1-targeting; focused_therapy:cancer_therapy,EZH1-targeting; focused_therapy:cancer_therapy,EZH2-targeting; focused_therapy:endocrine_therapy; focused_therapy:endocrine_therapy,androgen_axis-targeting; focused_therapy_class:CYP17A1_inhibitor; focused_therapy_class:EZH1/2_inhibitor; focused_therapy_class:antiandrogen,nonsteroidal,second_generation phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Abiraterone; sensitive_to:Abiraterone + Tulmimetostat; sensitive_to:Apalutamide; sensitive_to:CYP17A1_inhibitor; sensitive_to:CYP17A1_inhibitor + EZH1/2_inhibitor; sensitive_to:Darolutamide; sensitive_to:Darolutamide + Tulmimetostat; sensitive_to:EZH1/2_inhibitor; sensitive_to:EZH1/2_inhibitor + antiandrogen,nonsteroidal,second_generation; sensitive_to:Enzalutamide; sensitive_to:Gridegalutamide; sensitive_to:HM97662; sensitive_to:Proxalutamide; sensitive_to:Rezvilutamide; sensitive_to:Seviteronel; sensitive_to:Tulmimetostat; sensitive_to:Valemetostat; sensitive_to:antiandrogen,nonsteroidal,second_generation NOT therapy_recommendation:Abiraterone + Tulmimetostat:U; NOT therapy_recommendation:Abiraterone:U; NOT therapy_recommendation:Darolutamide + Tulmimetostat:U; NOT therapy_recommendation:Darolutamide:U; NOT therapy_recommendation:Tulmimetostat:U; preferential_trial_id:NCT07190300 recruitmentstates:NSW; recruitmentstate:NSW facility:2050 - Camperdown - Chris O'Brien Lifehouse; facility:2500 - Wollongong - Wollongong Hospital NCT07306832 catype:Acute myeloid leukaemia; catype:Cancer; catype:Haematological malignancy; catype:Leukaemia; catype:Myeloid leukaemia; catype_specific:Acute myeloid leukaemia phase:Phase 1 recruitmentstatus:RECRUITING; recruitmentstatus_active:true preferential_trial_id:NCT07306832 recruitmentstates:WA; recruitmentstate:WA facility:6009 - Perth - Perth Children's Hospital NCT07334301 catype:Cancer; catype:Neuroblastic tumour; catype:Neuroblastoma; catype:Neurological cancer; catype:Peripheral nervous system tumour; catype:Solid tumour; catype_specific:Neuroblastoma therapy:Bevacizumab; therapy:Dinutuximab; therapy:Irinotecan; therapy:Temozolomide; therapy:Topotecan; therapy:alkylating_agent; therapy:anti-GD2_monoclonal_antibody; therapy:anti-VEGF_monoclonal_antibody; therapy:cancer_therapy; therapy:cancer_therapy,GD2-targeting; therapy:cancer_therapy,VEGF-targeting; therapy:cytotoxic_chemotherapy; therapy:immuno-oncology_therapy,GD2-targeting; therapy:immuno-oncology_therapy,VEGF-targeting; therapy:topoisomerase_inhibitor; ; ; phase:Phase 1; phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Amsacrine; sensitive_to:Bendamustine; sensitive_to:Bevacizumab; sensitive_to:Bevacizumab + Dinutuximab + Irinotecan + Temozolomide + Topotecan; sensitive_to:Bevacizumab + Irinotecan + Temozolomide + Topotecan; sensitive_to:Busulfan; sensitive_to:Carmustine; sensitive_to:Chlorambucil; sensitive_to:Cyclophosphamide; sensitive_to:Dacarbazine; sensitive_to:Dianhydrogalactitol; sensitive_to:Dinutuximab; sensitive_to:Dinutuximab + Irinotecan + Temozolomide + Topotecan; sensitive_to:Ektomun; sensitive_to:Etirinotecan Pegol; sensitive_to:Etoposide; sensitive_to:Exatecan; sensitive_to:FF-10850; sensitive_to:Fotemustine; sensitive_to:Ifosfamide; sensitive_to:Irinotecan; sensitive_to:Liposomal Irinotecan; sensitive_to:Lomustine; sensitive_to:Lurbinectedin; sensitive_to:Melphalan; sensitive_to:Naxitamab; sensitive_to:Oratecan; sensitive_to:Orotecan; sensitive_to:Procarbazine; sensitive_to:SN38-SPL9111; sensitive_to:SNB-101; sensitive_to:Streptozotocin; sensitive_to:Temozolomide; sensitive_to:Thiotepa; sensitive_to:Topotecan; sensitive_to:Trabectedin; sensitive_to:Treosulfan; sensitive_to:alkylating_agent; sensitive_to:alkylating_agent + anti-GD2_monoclonal_antibody + anti-VEGF_monoclonal_antibody + topoisomerase_inhibitor; sensitive_to:alkylating_agent + anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; sensitive_to:alkylating_agent + anti-VEGF_monoclonal_antibody + topoisomerase_inhibitor; sensitive_to:anti-GD2_monoclonal_antibody; sensitive_to:anti-VEGF_monoclonal_antibody; sensitive_to:topoisomerase_inhibitor NOT therapy_recommendation:Bevacizumab + Dinutuximab + Irinotecan + Temozolomide + Topotecan:U; NOT therapy_recommendation:Bevacizumab + Irinotecan + Temozolomide + Topotecan:U; NOT therapy_recommendation:Bevacizumab:U; NOT therapy_recommendation:Dinutuximab + Irinotecan + Temozolomide + Topotecan:U; NOT therapy_recommendation:Dinutuximab:U; NOT therapy_recommendation:Irinotecan:U; NOT therapy_recommendation:Temozolomide:U; NOT therapy_recommendation:Topotecan:U; preferential_trial_id:NCT07334301 recruitmentstates:NSW,NZ; recruitmentstate:NSW; recruitmentstate:NZ facility:2031 - Randwick - Sydney Children's Hospital; facility:NZ.1023 - Grafton - Starship Children's Hospital NCT07354074 catype:Cancer; catype:Chronic leukaemia; catype:Chronic myelogenous leukaemia; catype:Haematological malignancy; catype:Leukaemia; catype:Myeloid leukaemia; catype_specific:Chronic myelogenous leukaemia; catype_specific:Leukaemia therapy:Asciminib; therapy:BCR-ABL1_inhibitor; therapy:cancer_therapy; therapy:cancer_therapy,BCR-ABL1-targeting; focused_drug:Asciminib; focused_therapy:Asciminib; focused_therapy:BCR-ABL1_inhibitor; focused_therapy:cancer_therapy; focused_therapy:cancer_therapy,BCR-ABL1-targeting; focused_therapy_class:BCR-ABL1_inhibitor phase:Phase 2 recruitmentstatus:RECRUITING; recruitmentstatus_active:true sensitive_to:Asciminib; sensitive_to:BCR-ABL1_inhibitor; sensitive_to:Bafetinib; sensitive_to:Bosutinib; sensitive_to:Dasatinib; sensitive_to:ELVN-001; sensitive_to:Imatinib; sensitive_to:Nilotinib; sensitive_to:Olverembatinib; sensitive_to:PD-180970; sensitive_to:Ponatinib; sensitive_to:TERN-701 (catype:Chronic myelogenous leukaemia OR catype:Leukaemia); NOT therapy_recommendation:Asciminib:U; preferential_trial_id:NCT07354074 recruitmentstates:QLD; recruitmentstate:QLD facility:4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre